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Antibody Targeting of Non Ionic Surfactant Vesicles to Vascular Inflammation
Elizabeth D. Hood
ABSTRACT

Cardiovascular disease (CVD) and particularly atherosclerosis is a leading
cause of morbidity in the developed world. Atherosclerosis and the rupture of
vulnerable atherosclerotic plaque cause 70% of deaths from CVD. The
progression of atherosclerosis has been identified as a pathological inflammatory
process. Targeting atherosclerotic drug therapies to inflammatory markers has
emerged as an important and growing research area. The adhesion molecule
CD44 has been implicated in the onset and build-up of atherosclerotic lesions
throughout the course of development. The research in this dissertation is aimed
at targeting anti-inflammatory therapy to activated vascular endothelium with
directed with an anti-CD44 antibody, IM7, conjugated to a non ionic surfactant
vesicle (niosome) drug carrier. The IM7 conjugated immunoniosome has been
shown to bind to endothelial and synovial lining cells in vitro.
The preliminary research is involved with the development of the drug
delivery vesicle, and the antibody linkage chemistry, along with an analysis of
vesicle characteristics and stability. A novel linking chemistry using
polyoxyethylene sorbitan monostearate and cyanuric chloride allows antibodies
to be conjugated to vesicle surface polymer groups without prior derivatization.

xv

Subsequent research tested the resulting ‘immunoniosome’s’ ability to bind to
target antigens with selectivity and specificity. Bovine aortic endothelial cells
activated with cytokines provide a model of inflammation. Analysis of binding
was done through fluorescent and scanning electron microscopy. In vivo uptake
of vesicles at sites of inflammation is size dependent. In order to overcome this
barrier to uptake, niosome suspensions were thermally extruded to create
uniform 200 nm vesicles. Further analysis of the efficacy of the system looked
at live cell uptake of the immunoniosomes measured by confocal and
transmission electron microscopy. Preparation for in vivo murine studies
required that the antibody component was modified to counteract the immune
response. Finally, the conjugation of antibody fragments to niosomes and the
binding and uptake of the vesicles in a live endothelial cell model is evaluated. A
viable drug delivery particle showing binding and cellular uptake capabilities in
inflammatory cells was produced by this research using a novel surfactantantibody linker.

xvi

1. Prelude
Immunotherapy, the use of antibodies to treat disease, is of great interest
in the fields of chronic infectious disease, cancer, cardiovascular, and arthritis
research, among others. In 1796, Edward Jenner used a cowpox virus to
develop a vaccine against small pox. He discovered that deliberate infection with
the virus brought on a mild state of the disease and a subsequent immunity to it1.
It was Paul Erlich at the beginning of the 20th century who originally discovered
antibodies and described the role they play in humoral immunity. He proposed
the ‘magic bullet’ concept of using antibodies to send therapeutic agents to target
cells2. He also imaged that “a carrier by which to bring therapeutically active
groups to the organ in question” would be advantageous3. Not until the
development of monoclonal antibody (mAb) production could his ‘magic bullet’
concept be realized. In the 1970s the B cell melanoma was identified as
producing a single type of antibody. Georges Jean Franz Köhler and César
Milstein invented the process to produce monclonal antibodies in 1975 for which
they won a Nobel Prize in Physiology or Medicine in 19844. Gregory Winter
developed techniques to humanize monoclonal antibodies for therapeutic uses5.
In 1965 Dr. Alec Bangham published ‘Diffusion Of Univalent Ions Across
Lamellae Of Swollen Phospholipids’ which is the seminal work of liposome6, and
therefore, vesicular drug delivery. More than forty years later strategic drug
delivery using phospholipid or other bilayer model structures continues to be
pursued for myriad applications such as vaccinations7, gene delivery8,
1

thrombolysis9, topical applications10, tumor targeting 11, vascular targeting12,
transdermal13, and ophthalmic treatments10,14 among many others.
The combination of immunotherapy and vesicular drug delivery originated
with Paul Erlich at the beginning of the 20th century. Almost eighty years later in
1981, Torchilin and Klibanov reviewed methods for immobilizing proteins on the
surfaces of liposomes15. Immunotargeting of drugs using an antibody vector
bound to a drug carrier has continued to be developed in the fields of cancer and
tumor therapy16-27, and cardiovascular research28-34. The use of immunotargeted
drug delivery to effect treatment and block progression of damaging inflammatory
processes has not been as widely pursued as cancer and tumor targeting, most
likely due to the more highly toxic effects that anticancer drugs have on healthy
tissues. However, the prevalence of cardiovascular disease and especially
atherosclerosis35, the challenges of restenosis of arteries after angioplasty, the
build up of plaques on stent implants, and other effects of inflammatory
processes in cardiovascular disease, as well as the questionable systemic side
effects produced by cardiovascular drugs36,37 provide motivation and
opportunities for a more succinct therapeutic approach.
Current research into innovative anti-atherosclerotic treatment includes
identifying and manipulating the inflammatory mechanisms consistent with the
progression of the disease from initial fatty streaks to fibrous plaques to
vulnerable complex lesions, uptake mechanisms of macrophage derived foam
cells38, and the identification of the regulatory factors controlling inflammatory
response in endothelial cells and uptake of lipoproteins39,40.

2

The hypothesis of this research is that an antibody conjugated non ionic
surfactant vesicle could be developed and targeted to inflammation with the
potential to provide therapeutic benefit by targeting specific inflamed tissues. In
order to test this hypothesis the following aims were pursued:

Aim 1. Develop and characterize a targeted drug delivery system using non ionic
surfactant vesicles conjugated to monoclonal antibodies specific to an
inflammatory target antigen.
Aim 2. Quantify and optimize the immunoniosome-antigen binding in fixed
culture aortic endothelial cells with respect to concentrations of both vesicle
concentration and antibody density using fluorescence microscopy and computer
image analysis.
Aim 3. Observe, describe, and quantify cellular uptake of immunoniosomes in
live cells using confocal and electron microscopy.
Aim 4. Once the drug delivery system is sufficiently described, develop a
protocol for the in vivo evaluation of the adherence and effect of the
immuniosomes encapsulating atorvastatin on plaque development in the ApoE
knockout mouse model.

The successful completion of these aims would produce a well described drug
delivery system ready for in vivo testing in an atherosclerotic model.

3

2. Literature Examination
2.1. Overview
Developing a drug delivery system provokes inquiry into several different
disciplines of research. The original idea was to develop a targeting system that
would treat atherosclerosis, specifically the vulnerable plaque of atherosclerosis.
Investigations into the recent developments and conclusions about
atherosclerosis revealed that the disease, like numerous other chronic
pathologies such as arthritis, lupus, and chronic obstructive pulmonary disease,
is an inflammatory disorder. Systemic implications and common mechanisms in
the build up of inflammatory disease are demonstrated by the high incidence of
atherosclerosis in rheumatoid arthritis patients without traditional risk factors for
the disease41. The onset and characteristic phases of atherosclerosis are
described, as well as the mechanisms of inflammation and the disease
progression. Literature reviews of atherosclerosis lead to investigation of other
inflammatory pathologies as a means to identify potential treatment strategies.
Furthermore, the mechanisms of disease onset and progression provide
targeting strategies; cellular adhesion molecules are mediators of progression of
atherosclerosis, among other inflammatory diseases, and are reviewed generally,
and the candidate adhesion molecule, CD44 specifically.
Identifying the appropriate drug delivery vehicle provoked research into the
large body of work representing drug targeting generally, vesicular drug
targeting, and liposomal and niosomal drug delivery specifically. Drug targeting
may be directed passively or actively; active targeting is usually mediated with a
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vector molecule, and some of the methods and applications of actively targeted
drug delivery are reviewed. Finally, a review of targeted imaging and therapy in
cardiovascular medicine is reviewed.
2.2. Cardiovascular Disease and Atherosclerosis
2.2.1. Implications of Cardiovascular Disease
The American Heart Association (AHA) lists prevalence among Americans
of having one or more types of cardiovascular disease (CVD) at 37.1% for 2004.
Over 36% of all deaths of Americans in 2004 were attributed to CVD35. Of the
different types of CVD, coronary heart disease and its underlying cause,
atherosclerosis, is the largest single cause of death42.

Atherosclerosis is a type

of arteriosclerosis, which describes the thickening and hardening of the arteries
generally. Atherosclerosis is the build up of lipids, cholesterol, calcium, cellular
waste, and fibrin and the proliferation of smooth muscle and inflammatory cells
within the sub endothelial space of medium to large arteries43, specifically
including the aorta, carotid, coronary, and peripheral arteries44. This evolving
accumulation of plaque causes narrowing of the arteries reducing the lumen and
the area available for blood flow, and decreases flexibility of vessels to absorb
the pressures created by blood flow. Stenosis is defined as “the constriction or
narrowing of a passage or orifice”45.
Atherosclerotic plaques are prone to erosion and/or rupture which
produces a release of core lipid and inflammatory contents into the blood stream.
As the coagulation factors in the blood contact the inflammatory tissue factor (TF)
expressed by the macrophages and the smooth muscle cells, along with other
5

expressed materials, a blood clot or thrombus forms in the lumen of the blood
vessel42. A thrombus is the product of the coagulation cascade of the blood; the
platelets activated by thrombin form a plug immediately and are further enforced
as fibrin fibers are formed by the cascade of coagulation factors46. This process
is necessary for hemostasis, to reduce blood loss in a damaged blood vessel, for
example, however the formation of occlusive thrombi as a result of plaque
rupture is the major instigating factor of coronary events47. Additionally it has
been shown that the plaque’s composition is a greater predictor to susceptibility
to rupture than size, or degree of stenosis42. In fact, many plaques prone to
rupture do not appear to be severely stenotic in a coronary angiogram48-51.
2.2.2. Atherosclerosis Development
Traditionally, atherosclerosis was considered to be a passive lipid
processing disorder with plaques gradually evolving over time to eventual
occlusion of the blood vessel. In this view the blood vessel itself is considered to
be an ‘inert tube’, not a dynamic structure interacting with blood and extracellular
matrix elements and cells, and proteins, which are seen in the normal artery but
also actively contribute to the progression of the disease.
Plaques may form as either stable, or unstable, vulnerable. Stable
plaques are characterized by a thick fibrous cap, a small core of lipid materials
and an unchanged lumen area, whereas vulnerable plaques are characterized by
a thin fibrous cap covering a large lipid core containing inflammatory cells.
Atherosclerosis is classified in stages assigning levels of severity to
plaques as they develop as seen in Figure 2.144. The initial stage, Phase 1, is
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the development of the fatty streak and proliferation of monocytes; the
endothelium may be unaffected at this stage and no symptoms are evident52 as
the vasculature compensates by ‘remodeling’ and maintaining the size of the
lumen53.

Figure 2.1 The Stages of Atherosclerotic Plaque Development. From 47.
Figure 2.2 shows an outline of the stages describing the disease
progression as defined by atherosclerotic lesion development and architecture47.
At the first stage the small lesions are of three types of increasing complexity;
type I consists of lipid-filled foam cells derived from macrophages. Type II
lesions contain smooth muscle cells and lipids from the extracellular matrix along
with fatty foam cells, and in type III lesions the smooth muscle cells are
immersed in connective tissue, fibrils and lipids54. Phase 2 is described as
advanced, with pre-stenotic lesions with potential to rupture, and progresses into
either Phase 3 or 4. Plaques at Phase 2 are either type IV, or type Va; the
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former characterized by a large lipid volume and smaller fibrous cap, and the
latter having a more extensive cap47. Phase 3 lesions are type VI developed
from type IV or Va lesions that have ruptured or eroded and form non occlusive
thrombi.
Phase 4, as shown in Figure 2.2, is the alternate path from Phase 2, and
has severe characteristic symptoms from type VI lesions. Occlusions may be
constant or periodic and present clinically as acute coronary syndrome. Because
a third of occlusive thrombi come from non stenotic plaque disruption the
syndrome may not be obvious until there is severe sudden ischemia or a
myocardial infarction (MI)47. Finally, in Phase 5 lesions are type Vb or Vc and
are either, respectively, calcified or fibrous and may both cause angina (chest
pain due to constricted oxygen flow) or ischemia44.

Figure 2.2 The Phases of Atherosclerosis. From 55
To further complicate an intricate process, the progression of
atherosclerotic plaques vulnerable to rupture and thrombus formation and their
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triggering events are not homogenous across different areas of the vasculature.
Plaque disruption is a critical trigger for acute events in coronary arteries, less so
in the carotid, and in the peripheral arteries thrombogenicity (the propensity to
form thrombi) is more crucial42.
2.2.3. Atherosclerosis and Inflammation
Inflammatory processes play a role in vascular disease, rheumatoid and
osteoarthritis, chronic obstructive pulmonary disease, and inflammatory bowel
disease, lupus, among others. The inflammatory process is characterized by
accumulation of inflammatory cells, leukocytes, and macrophages that
perpetuate the process and contribute to tissue destruction.
Once understood to be a disorder of lipid accumulation and cholesterol
metabolism, atherosclerosis is now described as a “chronic inflammatory disease
of the arterial system”56; inflammatory factors are implicated in every phase of
plaque development.

Endothelial cells contacting flowing blood mediate

interactions of underlying vessel tissue with blood cells and components. In
normally functioning endothelium, which forms a monolayer of cells on a
basement membrane that cover the intimal layer, expression of inflammatoryresponse cellular adhesion molecules (CAMs) and the subsequent attachment of
circulating leukocytes, is minimal42.
There is general agreement that atherosclerosis begins with an inciting injury
to the endothelium provoking an inflammatory immune response57. When normal
homeostasis is not restored, endothelial cell dysfunction continues as the
disease progresses58. It is the expression of adhesion molecules and the influx
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of leukocytes that perpetuate the disease throughout the process. Vascular
adhesion molecule-1 (VCAM-1) has been shown to play a major role in leukocyte
recruitment, binding to monocytes and T lymphocytes59. Further description on
the role and mechanisms of adhesion molecules in the inflammatory process will
be discussed in Section 2.3. A monocyte crossing the endothelium and entering
the tunica intima becomes a tissue macrophage, which then takes up lipids and
lipoproteins, in particular oxidized low density lipoprotein (LDL) in the plaque and
further transforms into a foam cell60. The build up of foam cells is a characteristic
of plaques. The foam cells produce pro-inflammatory cytokines which further
provoke immune response in the plaque and promote reactive oxygen species61.
Eventually the foam cells accumulate in the center of the lesion, die, and form a
necrotic core within the plaque. Death of the foam cells is attributed to either
apoptosis (programmed cell death) or the toxic effects of oxidized lipoprotein
uptake62.
The products of the inflammatory cells within the plaques disrupt the stability
of the fibrous cap covering the plaque. Macrophages and smooth muscle cells
release proteinases, such as collagenase and elastase, which break down the
structural proteins collagen and elastin. The degradation of elastin also disrupts
the ability of cells to move though the plaque61.
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2.3. Adhesion Molecules
Cellular adhesion molecules (CAMs) mediate blood -endothelial cell
interactions common to all segments of the vasculature under physiological or
pathological conditions 62. They are glycoproteins which have cytoplasmic,
transmembrane and extracellular domains63. CAMs are expressed by nearly
every cell type55, and are characterized by strong ligand binding. They
participate in cell to cell and cell to matrix interactions and in some cases also
signalling, migration, motility, gene transcription and differentiation64.
As was mentioned previously, a hallmark of endothelial dysfunction at the
initiation of atherosclerosis is the persistent adherence of circulating leukocytes
and their subsequent uptake into the tunica intima65. The inflammatory cells are
recruited by CAMs. CAMs expressed by the endothelium include intercellular
adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and
platelet-endothelial cell adhesion molecule-1 (PECAM-1), integrins, and
selectins66.
Once the adhesion molecules bind with monocytes, macrophages,
lymphocytes or platelets, those bound elements become activated themselves,
and release proinflammatory cytokines, membrane receptors, and a myriad of
enzymes, including the interleukins, tissue necrosis factor alpha (TNF-α),
interferon-α, and numerous others. Cytokines have been shown in increase the
expression of adhesion molecules including TNF-α, and interleukin-1 β (IL-1β)
and increase the binding of leukocytes to the endothelium67. The expression of
inflammatory proteins creates a positive feedback loop by further inciting uptake
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of inflammatory cells, promoting aggregation of oxidized LDL on the endothelial
surface and thus causing injury to the endothelium, and excreting further
inflammatory mediators68.
Since VCAM-1 is at the forefront of monocyte recruitment in lesion formation69
it has been identified as a potential therapeutic target and has been widely
studied70.

In knock out gene studies with mouse models the elimination of

VCAM-1 but not ICAM-1 was shown to reduce plaque formation in
atherosclerotic mice71. In vitro studies with monocytes co-cultured with
endothelial cells showed that adhesion was reduced when cells were treated with
antibodies raised against VCAM-1 and E-selectin, but not P-selectin61. Levels of
expressed VCAM-1 are used as a measurement in the efficacy of drug therapy72.
Adhesion molecule P-selectin is expressed on activated endothelial cells and
platelets. Targeting P-selectin demonstrated therapeutic efficacy in an
atherosclerotic mouse model which are cross bred with a P-selectin null mouse
model. Reduction in plaque formation and proliferation of leukocytes was
observed. However, the presence of soluble P-selectin in the bloodstream
complicates the strategy73.
Depending on the therapeutic strategy, these adhesion molecules could
provide drug targeting candidates. There have been numerous studies using
anti-VCAM74, anti-ICAM-175, and the anti-selectins76 antibodies as targeting
vectors which show great potential in vitro, however, there has been very little
translation of these studies in vivo over the last decade. Collaboration with
arthritis researchers70 led to the investigation of another adhesion molecule
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candidate, CD4477, ligand to hyaluronan (HA), a polysaccharide a major
component in the extracellular matrix (ECM) of mammalian cells. The
interactions of CD44 and HA have been implicated in cancer, autoimmune
diseases, and inflammatory processes78.
2.3.1. Adhesion Molecule CD44
CD44 is a family of adhesion molecules that are characterized by their
function, and mainly described as hyaluronan receptors. There are 10 standard
isoforms and 10 variant isoforms of CD44, and the most populous is the CD44s
isoform. The variation among the forms is found in ECM domain of the structure
and accounts for the isoforms variation in function78. CD44 isoform CD44-v6 is
highly expressed in the smooth muscle cells of the intima and media of injured
arteries78, CD44 isoforms including CD44-v6 are expressed on the endothelium
suggesting regulatory function of growth factors28 CD44 v10 is expressed by
aortic endothelial cells28. Isoforms CD44-v3 and CD44-v6 where shown to be
expressed on plaque microvessel, whereas CD44H and CD44v6 both express on
endothelial cells after exposure to IL-1β and TNF-α. Cd44H, CD44-v5, CD44-v6,
CD44-v7/8 isoforms are all expressed on macrophages and are all highly
regulated by the cytokines74. CD44 and HA were shown to mediate leukocyte
endothelial cell adhesion, previously thought to be the sole domain of the selectin
family79. These studies taken all together indicate that CD44 isoforms are
implicated in the pathogenic inflammatory process of atherosclerosis and that
their role is highly complex and regulated.
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Interruption of the inflammatory process has been studied using CD44
blocked by antibody IM7 (anti-CD44)80. Expression of CD44 and its variants was
augmented when exposed to pro-inflammatory cytokines within human
atheroma, implicating CD44 expression with the pathogenesis of arterial
diseases74. CD44 was further implicated in the progression of atherosclerosis.
Hyaluronan was shown, in a low molecular weight form, to stimulate vascular
cellular adhesion molecule (VCAM-1) and proliferation of smooth muscle cells
(SMC), whereas high molecular weight forms of HA inhibit SMC proliferation81.
Atherosclerotic prone ApoE-deficient mice bred with CD44-null mice showed a
50-70% reduction in aortic lesions compared to CD44 heterozygous and wild
type mice 82. These results suggest that CD44 promotes atherosclerosis by both
mediating inflammatory cell recruitment to atherosclerotic lesions and by altering
smooth muscle function 81.
2.4. Drug Targeting
Drug targeting is a strategy aiming at the delivery of a compound to a
particular tissue of the body. Drugs can be delivered singly or in large amounts
by using drug carriers. Drug carriers are substances that facilitate timecontrolled delivery, organ-specific targeting, protection, prolonged in vivo
function, and decrease of toxicity of drugs to unspecified tissues. Drug targeting
may allow for increased permeability of membrane barriers, allowing for
molecular movement between tissues. Ideally, drug targeting would provide a
high local concentration of drug at the site of disease and a concentration below
levels of toxicity in healthy tissues81. Examples of drug carriers are myriad,
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including but not limited to, liposomes, micelles, polymeric vesicles, and nanoparticles6.
Normal administration of drugs or therapeutic agents does not allow for
concentrated accumulation of drug at diseased sites due to an essentially
uniform distribution of drug throughout the body. In order to adequately treat
affected sites using traditional systemic administration high doses of drug must
be delivered. This not only increases costs, but also can create toxic side effects
as normal tissues and organs are needlessly exposed to pharmaceuticals 83.
Encapsulation of drugs for passive targeting, either by liposome 81, niosome 68,
or polymeric 81 media has shown increased retention time, decreased therapeutic
dose, and reduced toxicity to unspecified tissues.
Targeting schemes include direct application into the affected organ or
tissue, passive application to tissues through leaky vasculature-tumors, infarcts,
or inflammation. Another scheme is physical targeting, which can be based on
manipulating an abnormal pH or temperature at the target by using pH or
temperature sensitive drug carriers. Magnetic targeting of drugs to affected
areas within the body can be achieved using paramagnetic carriers attached to
magnetic drugs and then directed by an external magnetic field84. Active drug
targeting is generally described as the use of a vector molecule with a high
specific affinity toward the affected tissues bound to a drug or drug carrier 21.
Active drug targeting using a monoclonal antibody vector is the approach of this
research.
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2.4.1. Vesicular Drug Delivery
Among drug carriers listed previously, vesicular drug carriers provide
advantages over individual single molecule carriers. They not only allow greater
payload of drug to be delivered, but also provide isolation of the drug from the
system overall and thereby provide protection immune responses. Vesicle
bilayers mimic biological membranes which enhance absorption of encapsulated
drugs across cell membranes and into tissues. Vesicular drug delivery allows
protection of the encapsulated drugs from enzymatic degradation85, prolonged
circulation time, and therefore a reduced rate of release of drug into the
bloodstream86, and the shielding of an immunogenic drug from recognition by the
reticuloendothelial system (RES)85.
2.4.1.1.

Liposomes

Vesicles made from organically-derived amphiphilic (having both
hydrophilic and hydrophobic moieties) phospholipids, like those that comprise
cell membranes, are the most prevalent and widely researched drug delivery
particle87. These liposomes, or “fat bodies” from the Greek, were first observed
by researchers in the 19th century using lecithin in blood clotting studies. In
1911, Otto Lehmann published a representation of micrograph of what he called
‘artificial cells’ which resembled a dispersion of multi-lamellar liposomes 88. Even
though work with lecithin dispersions continued the properties and potential
applications of these dispersions were not described until Dr. Alec Bangham and
his colleagues published their seminal work 89. They described how these
particles, formed from the hydration of lipid thin films, retained some of the
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hydrating solution that they formed in within their core creating a ‘permeability
membrane’. Researchers used the self assembly vesicles to study biological
membranes and other applications, and these pursuits eventually led them to
drug delivery. Liposome applications that developed thereafter, both
commercially and within academia, are many and varied including multiple
scientific disciplines; medicine, immunology, diagnostics, cosmetics, ecology,
cleansing and the food industry 90. Promising laboratory research did not always
translate to commercially viable scale-up within the medical realm, however, and
repeatability and stability problems caused early liposome based start-up
pharmaceutical companies to fail91.
Liposomes’ interaction with cells has been studied not just for drug
targeting purposes but also in developing further understanding of cell-cell
interactions. Liposomes’ interaction with cells can be characterized in four ways
shown in Figure 2.3. First, the liposome may exchange material, either lipids or
proteins, with cell membranes. Secondly, liposomes may bind or adsorb with
cells, and once bound may be internalized through either endocytosis or
phagocytosis. Alternately, the bound liposome may instead fuse with the
membrane. Whichever of these possibilities arise is dependent on the size,
charge, and makeup of the vesicle92.
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Figure 2.3 Vesicular Interactions with Cells. (Adapted from Lasic 81)
The problem of early and rapid elimination from the bloodstream of the
first liposome formulations was solved by the development of the ‘Stealth’ or
‘sterically stabilized’ liposomes93. The addition of small amounts of a hydrophilic
polymer, frequently polyethylene glycol (PEG), extended the half life of a ‘classic’
liposome from a few minutes to several hours94. Researchers have developed
several synthesis techniques to enhance desired characteristics. Along with
varying methods of synthesis, vesicular drug delivery also varies in physical
makeup. Multiple vesicle layers have been shown to enhance release rates
significantly when compared to free drug and uni-lamellar vesicle delivery95.
Development of commercially available vesicle applications, passive and
active, have been pioneered by cancer research96. One multiple-application
technology that is being developed commercially is called DepoFoam™ and is
made by the Swiss company SkyePharma. They produce foams of spherical
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lipid-bilayer aqueous chambers, or multivescular liposomes that are used to
encapsulate drugs, vaccines, DNA, peptides or large particle bio-therapeutics
which may be administered locally or systemically97.
2.4.1.2.

Niosomal Drug Delivery

Niosomes are analogues of liposomes synthesized from synthetic
surfactants rather than organically derived phospholipids. They are also self
assembly vesicles usually composed of a surfactant, cholesterol and a steric
stabilizer, such as dicetyl phosphate98. Niosomes behave similarly to liposomes
in vivo by prolonging circulation time of the encapsulated drug and altering
chemical distribution within the body 99,100. However, niosomes have advantages
over liposomes as drug carriers, including chemical stability, lower cost, easier
storage and handling, and a reduced likelihood of becoming toxic through
oxidation 8. Like liposomes, niosomal encapsulation reduces toxicity of drugs to
untargeted tissues in many different applications and therapies. Niosomal drug
delivery has been studied using various methods of administration 7 including
intramuscular 10, intravenous 101, peroral, 102and transdermal 103. Niosomes can
be used to solubilize insoluble agents86. Nebulized surfactants entrapping alltrans-retinoic acid were delivered as an inhaled aerosol reducing the drug toxicity
and altering the pharmacokinetics 84. In addition, as drug delivery vesicles,
niosomes have been shown to enhance absorption of some drugs across cell
membranes 26, to localize in targeted organs 17 and tissues 84,104, and to elude
the RES 105. Cellular uptake of niosomes can be via endocytosis 106; however
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they have been shown to bind and fuse with cell plasma membranes via cellular
receptors when vesicle surface charge is sufficiently negative 26.
Niosome entrapment of methotrexate administered orally and
intravenously in a mouse model was shown to increase residence time in the
body and decrease clearance27. Tumor targeting of niosomal formulations of
doxorubicin26, vincristine sulfate105, cisplatin107, camptothecin24, shown increased
residence times and anti-tumor efficacy compared to free drug.
Recent examples of niosomal drug delivery research are varied and
include topical vaccination generally24 and of DNA108,106 and treatment of
acne109, alternate insulin delivery methods2, oral immunizations110, transdermal
anti-inflammatories111, and ophthalmic applications112, among others.
2.5. Background and Current Practices in Antibody Mediated Drug Targeting
The discovery of the nature of antibodies and the development and
refinement of monoclonal antibody production had a revolutionary effect of the
treatment of infectious disease and has provoked the pursuit of numerous
targeting strategies in cancer and cardiovascular medicine113.
Anticancer therapy, and especially tumor targeting, has been the
forerunner in the development of liposomal 28, niosomal 32, and other drug
delivery systems32 and is the most widely pursued application of antibody
mediated targeted drug delivery 32. Early clinically approved and commercially
available nanoscale (200 nm or smaller) systems for untargeted drug delivery
were developed for cancer treatment and include DOXIL®, a liposomal
encapsulation of doxorubicin (1995), and Ambisome®, liposomal amphotericin
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(1990)32. Innovations in vesicle-antibody linking schemes were also driven by
cancer researchers. In order to increase circulation time and decrease the rapid
clearance of classic liposomes from circulation, polymer groups (usually PEG
groups) were added to liposomes surfaces32. These liposomes showed
favorable passive targeting to tumors and leaky vasculature. The addition of site
specific targeting vectors, monoclonal antibodies and fragments most prevalent
among them, provided active targeting capabilities to improve therapeutic
capacity and decrease non specific tissue interactions. When antibodies were
coupled to the vesicle surface of a PEG coated liposome both the ability of the
antibody to bind to the surface of the liposome was hindered, as well as its
capacity to attach to the targeted antigen site68. The PEG groups that inhibited
the desired qualities of an immunoliposome provided an attractive site for
antibody attachment and increased antibody-antigen site recognition versus
attachment of antibodies at the vesicle surface34.
Liposomal immunotargeting has been used extensively for cancer and
cardiovascular applications. Antibody-vesicle conjugation chemistries are varied
but there are similar physical configurations of linkers that result in increased
efficacy of antigen binding when the ligand is attached distal to the vesicle
surface. This increases rotational freedom of the targeting moiety and decreases
hindrance by the bulky polyethelyne glycol (PEG) groups at the surface of a
‘stealthy’ liposome114. Attachment of ligand distal to the vesicle on a PEG
terminus was found to have increased binding to target cells compared to
attachment on the surface31. Development of a polyethylene end group on a
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phospholipid molecule functionalized with cyanuric chloride allowed for
attachment of antibodies without prior derivatization of antibodies

115

. Improved

tumor targeting was shown using niosomes with PEG-glucose conjugates using
a paramagnetic agent encapsulant28. Echogenic liposomes conjugated with
targeting antibodies show in vitro promise for simultaneous imaging capabilities
and targeted therapeutics 116.
Differing antibody-polymer linkage schemes were developed, usually by
creating a functionalized PEG group coupled to a phospholipid molecule (‘linker
lipid’92,95,117-126) and incorporated into the vesicle membrane for subsequent
antibody or targeting vector coupling. These schemes included differing
formulations of thioether bonds coupling an antibody to the terminal end of a
PEG group, either by activating a maleimide group attached to a thiolized
antibody

7,8,91,99,100,102,127-131

, or hydrazide group reacted with an aldehyde group

on an oxidized antibody10,99,132-135, among others. An end-group functionalized
PEG linkage was developed that did not require activation or functionalizing of
the antibody105. A cyanuric chloride molecule to was added to the head group of
a membrane component phospholipid linking a PEG molecule to that, and then
another cyanuric chloride molecule to the terminal end of the PEG which would
then be coupled to an antibody via nucleophilic substitution115,136-138.
Although the group subsequently found unfavorable in vivo blood
circulation times of their immunoliposome (IL) formulation19,28,29,139, subsequent
studies have identified the Fc region of the whole antibodies used as the culprit in
provoking an immune response, and promoting rapid clearance of ILs.
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Researchers have demonstrated this with liposomes conjugated with anti-HER2
monoclonal antibody fragments (the protein HER2 is a member of the epidermal
growth factor family and is over-expressed in breast cancer and implicated in its
pathogenesis) 105. The anti-HER2 IL-were shown to have identical blood
residence time as compared to non-targeted sterically stabilized liposomes in
vivo, and further showed no increased clearance with subsequent
administrations. Incubation with cells that over-expressed HER2 had a 700 fold
increase in cellular uptake of drug compared to non-targeted liposome140. Active
targeting of niosomes was shown using glucose targeting with the inclusion of a
glucose-palmitoyl glycol chitosan conjugate in a sorbitan monostearate
niosome141. Improved tumor targeting was shown using niosomes with PEGglucose conjugates using a paramagnetic agent encapsulant142. To our
knowledge there is no literature on any other group studying antibody targeting of
niosomes.
2.6. Cardiovascular Antibody Mediated Imaging and Therapy
2.6.1. Imaging and Therapy

Diagnostic medical imaging is a prevalent and non invasive technology
widely used in obstetric and cardiovascular disciplines, among others.
Innovations in technology have transformed ultrasound (US) images from grainy
and poorly-resolved to sharp digital imaging115. The non invasive nature of US
tissue penetration makes it an attractive therapeutic strategy. Active therapeutic
targets within the cardiovascular system include atherosclerotic plaques, or other
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areas of damage within the vascular walls and bed, infarcts, thrombi and blood
elements115. US targeted imaging 88 and imaging driven therapy of thrombi has
been widely pursued143. Contrast agents have been studied not just for the
ability to enhance ultrasound (US) imaging but also for thrombolytic potential
created by the very high localized pressures created when US exposed contrast
agents burst driving their therapeutic load into target thrombi88. Ultrasound
imaging of a liposomal combination of echogenic contrast agent and drug
delivery vehicle has shown also the ability to guide therapy and disrupt thrombi
88,144

. Additionally contrast agents, or ‘microbubbles’, have been studied as

potential gene delivery vectors by exploiting the explosive cavitation of US
exposure driven bursting to propel plasmid DNA into vessels88.
Detection of expressed adhesion molecules as antibody directed contrast
agents bind locally can be used to identify inflammation and early detection of
cardiovascular pathologies115. Atherosclerotic animal models demonstrate the
facility of targeted MRI imaging of thrombus producing ruptured plaque to
potentially guide therapy136. Atherosclerotic plaques can also be imaged using
targeted US contrast techniques accessing either expressed inflammatory
adhesion molecules on the endothelial surface or activated bound leukocytes
through contrast agent antigen receptors136.
The potential to direct therapy through imaging and simultaneously control
drug delivery and release could address several challenges of inflammatory
pathologies as greater understanding of the complex chemical and molecular
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interactions of inflammatory processes drive plaque buildup, instability and
vessel restenosis115.
2.6.2. Current Research in Vesicle Mediated Drug Delivery in
Inflammation and Cardiovascular Disease.
Reviews of cardiovascular targeted drug delivery cover the myriad
applications pursued in targeting pharmaceuticals to cardiovascular disease145.
Thrombus treatments and imaging have been targeted with and without antibody
or other protein mediation, and through magnetically driven thrombolytics.
Atherosclerotic lesions, circulating blood cells and elements, and endothelial cells
have all been addressed as therapeutic targets. In treatment of lung disease,
aerosols have been developed to accumulate drug delivery in the lungs92, as
have antibody-mediated delivery to antigens in the lungs146, to malignant lung
disease145, and immuno-liposomes directed to the pulmonary endothelium30,147149

. The mechanisms and techniques of successful targeted and untargeted

accumulation of drug delivery vesicles in the pulmonary endothelium are relevant
to developing other vascular inflammation strategies.
Imaging of pathogenesis in the heart through targeting has been studied
post myocardioal infaction and in myocarditis. Liposomal accumulation has been
shown in ischemic heart tissue 150. Liposomal cardiovascular targeting has been
reviewed in detail specifically32. While limited to intravascular tissues only, in
vitro and in vivo studies of liposomes and immunoliposome as a drug carriers to
many antigens were addressed151. Among the topics reviewed was the targeting
of vessel wall injury. Multiple pathologies, atherosclerosis, and coronary
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thrombosis among them, are initiated by vessel injuries which promote platelet
activation and binding. Early detection of the disrupted endothelium through
targeting of expressed antigens providing a ‘signal’ has been studied. This
included an in vitro examination of targeting extracellular matrix antigens where
collagen gaps provide binding sites for liposomes conjugated with antibodies to
type 1 collagen, and similarly proven against laminin and fibronectin also. These
studies showed good affinity, specificity, and selectivity. Also the liposomal
antibody-antigen binding mimicked nature: cell binding studies showed that
liposomes conjugated with antibodies provided a dissociation constant (describes
the affinity between ligand and protein) on the order of 10-9 M, which corresponds
to physiological antigen to free antibody binding constants151.
Human endothelial cells incubated with immunoliposomes conjugated with
cell surface antibodies (anti-T antigen A25) were shown to bind at 4˚C and
endocytose 30% of bound ILs at 37˚F. Liposomes and ILs were seen to
accumulate in an ischemic heart providing imaging and therapeutic targeting
potentials to damaged myocardium. Positively charged untargeted liposomes
were observed to accumulate in experimentally produced myocardial tissues as
early as the 1970s; further studies confirmed further the propensity for liposomes
to accumulate in depolarized myocytes and in ischemic tissues in general151.
These findings provided the groundwork for liposome passive targeting to
ischemic tissue and infarcted heart tissue.
Active targeting of anti-myosin conjugated ILs to myocardial tissue was
studied in vivo and showed good accumulation in the ischemic myocardial tissue.
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This effect is limited in traditional liposomes when access is restricted because of
lack of blood supply and vesicles are eliminated by the RES before accumulation
occurs. As with other traditional liposomes, surface alterations by the
incorporation of PEG groups along with antibodies provided targeting and
prolonged circulation time showed greater penetration152.
Another consequence of ischemia is the formation of lesions of the cell
membrane. Loss of membrane integrity is further exacerbated upon reperfusion
leading to cell death as cell contents are exposed and reperfusion injury ensues.
The capacity to target and seal lesions created in hypoxic in vitro conditions
using cardiocytes with immunoliposomes (ILS) shown to be effective, greatly
increasing post hypoxic cell viability after IL incubation. Furthermore, hypoxic
and IL treated cells were shown to grow normally in culture after the event109.
Immuno-liposomes targeted to intercellular adhesion molecule 1 (ICAM-1)
were shown to bind to and be internalized by epithelial cells in vitro,
demonstrating their potential of the anti-ICAM antibody bearing vesicles to deliver
an anti-inflammatory drugs to sites of increased ICAM expression 153. With an
aim to combat restenosis following coronary angioplasty, liposomes conjugated
with peptide sequences were created to target to glycoprotein IIb-IIIa receptors
on activated platelets34. Platelet aggregation and deposition is implicated in the
pathogenesis of restenosis through deposition of growth factors and
inflammatory mediators. To increase circulation time they modified the vesicle
surfaces with an oligodextran polymer, analogous to the use of PEG groups to
elude the RES 152. The effect of stress by reactive oxygen species on
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endothelial cells is implicated in cardiovascular diseases making antioxidant
drugs therapeutic candidates. Antioxidant enzymes such as superoxide
dismutase and catalase make good therapeutic candidates but are rapidly
eliminated from the bloodstream, inhibiting their efficacy. Muzykantov’s group30
showed that by encapsulating the enzymes, which they coupled to PEGs, the
elimination was greatly reduced and the efficacy and bioavailability of the
enzymes were increased. Binding to expressed antigens in the endothelium in
vivo was shown by targeting angiotensin converting enzyme (ACE) and adhesion
molecules (ICAM-1 and PECAM-1). Vascular accumulation, endothelial uptake,
and increased antioxidant protection were all shown with this targeting
scheme136. ICAM-1, but not PECAM-1 was shown to be susceptible to
pathological stimulus, exhibiting increased expression and uptake in and by
endothelial cells. Anti-ICAM1 targeted immunoliposomes of 100-300 nm
diameters showed specificity of uptake compared to non specific antibodies or
large vesicle targeting115.
The aim of the literature review was to not only establish a foundation of
knowledge in the different disciplines involved in creating a targeted drug delivery
system but also to identify the most appropriate carrier system, antigen target,
mode of delivery and mechanism of uptake.
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3. Project Description
The objective of this project was to develop and test a drug delivery
system that could be targeted to vulnerable atherosclerotic plaque. Figure 3.1
shows the interdependent relationship of the physical elements needed to meet
this objective. In order to design the system effectively, the affinity of the drug
delivery vehicle must be established for both the drug of interest and the drug
delivery vector that will be targeting the biological site. The targeting vector is
chosen not only for its ability to seek and deliver the drug delivery system to the
site of interest but also to help facilitate the uptake of the drug on site. Obviously
the efficacy of the drug delivered must be appropriate to treat the affected site.

Figure 3.1 Interdependence of Elements of the Drug Delivery System.
The drug delivery vehicle that was chosen for the system is a non ionic
surfactant vesicle, or niosome. The vesicle’s stability, versatility, biocompatibility,
and cost made the choice compelling. Surfactant components available are
numerous, allowing versatility in formulation strategies to not only manipulate
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stability136 (the ability to retain the encapsulated component) but also to allow the
potential to incorporate various linkers to the vesicle surface105. The biological
target provides the therapeutic conduit, and therefore should be specific to the
disease pathogenesis and if possible, implicit in it. The development of
atherosclerosis and the morphological changes in plaque along the progression
of the disease provide varied targeting strategies105. The inflammatory
processes implicated in each progressive step of plaque development and the
shift in stability of the plaques have associated biomarkers which provide not only
a targeting potential for in situ drug delivery, but also a mechanism to interrupt
disease progression. Adhesion molecules are mediators in the process of
inflammation and make logical therapeutic targets70.
3.1. Development and Testing of an Immunoniosome
The use of an antibody-conjugated non ionic surfactant vesicle or
‘immunoniosome’ to target vascular inflammation is an original concept.
Niosome research has been largely in the realm of cancer154, immunization155,
and topical therapies156. The process of vesicle development included evaluating
the formation and stability of niosomes composed of sorbitan monoester
components that had been well described the literature and whose surfactants
were commercially available71. Liposome literature describes the widespread
use of polyethylene glycol (PEG) groups on the surface of liposomes, originally
incorporated to elude the immune system, as a desirable site for targeting vector
attachment. The addition of PEG may be accomplished by adding the polymers
after vesicle formation to linkers attached to phospholipids accessible on the
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liposome surface or by creating phospholipid PEG compound molecules and
incorporating those as the vesicles form157. A similar polymer group was
incorporated in one of our sorbitan ester surfactants but the stability of the
polyoxyethylene sorbitan monostearate (Tween 61) niosome was not favorable.
This led to investigating blending the surfactant components to evaluate the
potential to introduce a linking site while maintaining the desired properties of
stability and entrapment. Liposome literature reviews described multiple
schemes linking proteins to vesicles141. Cyanuric chloride has been used in the
past to adhere proteins to surfaces and was described as a linker in
immunoliposomes12,28,32,158. From these ideas I developed the linking chemistry
of the polyoxyethylene sorbitan monostearate functionalized with cyanuric
chloride in order to provide a protein binding site on the surface of a formed
vesicle. This is a novel process and a non-provisional patent application has
been filed and published 159. The resulting immunoniosome (IN), see Figure 3.2,
was tested in a fixed synovial lining cell model for specificity, selectivity and
binding. Adhesion molecule CD44 was identified as a target antigen implicated
in the progression of atherosclerosis160, so the binding studies were done with
anti-CD44 as the targeting vector.
Bovine aortic endothelial cells were used to test the ability of the niosomes
to binding to inflammatory cells specifically expressing target antigens. The
binding of fluorescent INs to cells was measured using a customized MatlabTM
program (see Appendix D), which relates the binding of immunoniosomes to the
cells relative to experimental variables.
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Figure 3.2 Immunoniosome Membrane Structure.
3.2. Binding and Uptake of Vesicles
Uptake of INs by cells was investigated. Prior to the live cell incubation
studies, changes in the synthesis process were necessary. Reduction of
niosome size by extrusion created niosomes of 200 nm, a size demonstrated as
preferential in uptake by atherosclerotic lesions148. Additionally, in some studies
antibodies were fragmented prior to conjugation and incubation with cells to
evaluate the ability of the linkers to attach Fab fragments. Studies showing
unfavorable uptake of whole antibody immunoliposomes implicated the
conserved Fc region of the antibody107,161, so in preparation for in vivo studies,
uptake of Fab conjugated immunoniosomes, as well as the uptake of whole
antibody targeted vesicles by cells was tested using confocal and TEM
microscopy.
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Finally, in order to test the efficacy of the system in vivo a protocol for a
study using an atherosclerotic mouse model and treated with atorvastatin
containing immunoniosomes compared to free drug treatment was developed
and approved by the USF Institutional Animal Care and Use Committee (IACUC)
and the US Army Medical Research and Material Command Animal Care and
use Review Office.
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4. Vesicle Development
4.1. Immunoniosome Synthesis Project Description
The development of the immunoniosome took place in four distinct
phases. In the first phase, the general formulation of the vesicle had to be
identified, synthesized, measured, and tested for viability. Niosome literature and
availability of components favored using surfactants from the sorbitan ester
family, both for stability, encapsulation capacity, and economy 30. Vesicles of
different compositions of those sorbitan esters, and their encapsulation and
retention capacities were evaluated using fluorescent dye as a drug model.
Chromatography, particle sizing, fluorescence intensity, and microscopy were
employed to purify and measure vesicle formulations162-164. Vesicles were
stressed with diagnostic levels of ultrasound to evaluate membrane stability.
Also of interest was the potential to create a ‘tuneable’ targeted drug delivery
vesicle that would not only be site specific but would have controlled release
upon activation with US exposure. The next phase was a refinement of the first,
and looked at the potential of blending surfactant components in quantities that
retained desired stability properties while providing potential linker candidates.
Once the blended formulation was established, the next phase involved the
development and evaluation of the linker chemistry. Finally, once the ability of
the surfactant linker to bind a monoclonal antibody to the surface of a niosome
was established the last phase tested the ability of the resulting
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‘immunoniosome’ to bind to a target antigen on a fixed cell using an activated
fixed synoviocyte as a cell model of inflammation.
4.2. Material and Methods
4.2.1. Introduction
The ability of lipids to form bilayer vesicles instead of micelles is
dependent on the hydrophilic-lipophilic balance (HLB) value of the surfactant, the
chemical structure of the components and the critical packing parameter (CCP)
which is the relationship between the structure of the surfactant including size of
hydrophilic head group, and length of lipophilic alkyl chain (Figure 4.1). The
formula is CCP =

v
where lc = the length of the alkyl chain, v = the volume of
lc a0

the hydrophobic chain volume, and a0= area of the hydrophilic head group115.
The HLB value can measured experimentally for each surfactant by reversed
phase thin layer chromatography165. The value represents a relative proportion
of the hydrophobic and hydrophobic groups comprising the molecule and
provides a guide for evaluating potential vesicle formation. Generally it has been
reported that HLB for sorbitan esters are between 4.0-8.0115. For of an HLB
value of greater than ~6, cholesterol must be added to the surfactant in order for
a vesicle to form166. The general form of a single bilayer vesicle is shown in the
left of Figure 4.1.
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Figure 4.1 Critical Packing Parameter and Bilayer Membrane. Left: Schematic
for calculating the critical packing parameter of an amphiphile (Adapted from
Uchegbu 1998115.) Right: Bilayer Membrane Structure
Niosomes are similar to liposomes in structure and methods of synthesis.
The fundamental component of both is an amphiphile, a molecule containing
both a hydrophobic and hydrophilic moiety, and the structure of the resulting
vesicle is formed by a single or multiple bilayer membrane enclosing an aqueous
core. There is a wide array of commercially available, inexpensive,
biocompatible surfactants that enable specified structural design of vesicles167.
Niosomes can form from many of these surfactants, and are commonly made by
the combination of a single alkyl chain nonionic surfactant and cholesterol, in
addition to an ionic electrostatic stabilizer, such as dicetyl phosphate. The
addition of cholesterol enables more hydrophobic surfactants to form vesicles
and suppresses the tendency of the surfactants to flocculate or form
aggregates167. The addition of cholesterol has been shown to lend greater
stability to the bilayer membrane by raising the gel liquid transition temperature of
the vesicle. This stability decreases leakage of the vesicles and stabilizes
against osmotic gradients168.
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The formation of single or multiple bilayer (lamellar) vesicles upon
hydration is a result of the amphiphilic surfactant’s (surface active agent’s)
interaction with the aqueous solution caused by the high interfacial tension
between the water and the hydrophobic alkyl chains. This tension causes the
hydrocarbon regions to associate simultaneously as the hydrophilic head groups
orient towards the water; the actions of each opposing force culminate in the
formation of the vesicle assembly 168. The thermodynamics of formation dictated
by Gibbs free energy (∆G-∆H−∆S≥0, at a given temperature) states that in order
for the self assembly to go forward there must be sufficient enthalpy (∆H) to
overcome the negative entropy of the system (-∆S) and the reduction in free
energy (-∆G). The van der Waals attractions, the hydrophobic-hydrophilic
interactions, hydrogen bonding, and electrostatic interaction contribute the
necessary enthalpy of formation. In order for the association of the molecules to
proceed there must be an energy gradient between their associated versus
isolated states, and Israelachvili stated that self assembly will proceed as long as
the interaction free energy per associated monomer µ N0 , (where N is the number
of associated monomers) is greater that the mean interaction free energy of the
isolated monomers; µ N0 < µ10 . This is true as long as µ N0 decreases with N, with

µ N0 reaching a limiting value 168. The energy gradient driven interactions of the
molecules described underlie the HLB dependence of vesicle formation
mentioned earlier as related to the shape and size of the hydrophilic head
groups, and the lengths of the hydrophobic alkyl tails that dictate the HLB
balance169.
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4.2.1.1.

Gel-Liquid Crystal Transition Temperature

Formation of lamellar vesicles is dependent on not only the components
themselves, but also on temperature. The bilayer structures have different
phases in which they exist. The gel state is the most ordered, and the liquid
crystal state is less ordered. Within the gel phase the alkyl tails of the
amphiphiles are crystallized and can not diffuse. In the liquid crystal state there
is lateral diffusion of the bilayer components. The liquid crystal phase of a
system always exists above the gel phase. In order for niosomal vesicles to form
the hydration must be set above the gel-liquid crystal transition temperature of
the surfactant167,169. The gel phase transition temperature of Span 60 is 57˚C,
and therefore the hydration and extrusion temperatures are set to 60˚C167.
4.2.2. Materials
4.2.2.1.

Chemicals

Niosome preparations and surfactant derivatization and treatments were
made from sorbitan monostearate (Span 60), sorbitan monopalminate (Span 40),
sorbitan monolaurate (Span 20), polyoxyethelene sorbitan monostearate (Tween
61), cholesterol, and dicetyl phosphate (DCP), diisopropylethylamine (DIPEA),
cyanuric chloride (CC), Triton-X 100, which all came from Sigma Chemical, St.
Louis, MO. Surfactant properties are listed in Table 4.2 in Section 4.2.3.1.
Fluorescent dyes, 5(6) carboxyfluorescein (CF) and 5(6) carboxyrhodamine (CR)
were obtained from Biotium, Hayward, CA. Phosphate buffered saline (PBS),
and Sephadex G50, Histochoice tissue fixative, Hank’s Balanced Saline (HBS),
Dulbecco’s Modified Eagle Medium (DMEM), Bovine serum albumin (BSA) and
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goat serum were obtained from Fisher Scientific, Suwannee GA. Collegenase P
was obtained from Roche Applied Science, Indianapolis IN. The Alexa Fluor©
488 protein fluorescent labeling kit came from Molecular Probes (A20181).
4.2.2.2.

Vesicle Characterization Materials and Methods

Particle analysis included light scattering, single particle optical sensing
technology, optical microscopy, chromatography techniques and fluorescence
measurements. Fluorescence changes were measured to evaluate
encapsulation by the vesicles and leakage over time. The mean particle size and
distribution of formed vesicles were determined using an Accusizer 780A optical
particle analyzer from Particle Sizing Systems. The algorithm behind the PSS
technology combines single-particle light scattering and light extinction
technologies. Light scattering is used for particles less than 1 µm in diameter,
with a lower limit of 0.5 µm, and light extinction is used for particle greater than
1.0 µm. Small volumes (0.005 - 0.1 ml, depending on concentration) of niosome
suspensions are added to the diluting chamber and diluted and cycled through
the through the sensor until the concentration of particles is such that they pass
through individually, eliminating ‘coincidence’ of particles. As the particles pass
through a uniformly illuminated ‘optical particle sensor’ they obscure part of the
sensor signal which produces an output pulse from a 35mW infrared diode. The
pulses represent these discrete particles whose magnitude corresponds to a
particle diameter. Figure 4.2 shows a schematic diagram of the auto-dilutor
system. The accumulation of the pulses, interpreted by a signal processor,
produces a particle size and concentration distribution plot (PSD). Figure 4.3
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shows a PSD plot of a polystyrene standard containing a mixture of particles with
three different diameters, 0.7, 1.0, and 5 µm. The known sizes and
concentrations of the standards allowed for calibration and verification of the
instrument.

Figure 4.2 Autodilution Scheme of Particle Sizing System. (PSS User manual)
The vesicle suspensions were also characterized by observing the
changes of their chromatography elution profiles details of which are described in
the GEC purification below. Essentially, the constituents of a vesicle suspension
are separated by size as they elute through a packed bed matrix, and those
constituents can be measured using UV absorbance or fluorescence intensity.
By comparing changes in elution chromatograms the relative stability of the
formed vesicles can be monitored.
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Figure 4.3 Particle Size Distribution Plot of a Mix of Three Sizes of Polystyrene
Latex Standards.
Fluorescent dyes were used to study entrapment and retention in the
niosomes because of the sensitivity and precision of fluorescent measurements.
We were able to observe incremental changes as small as tenths of nano-moles
of dyes in suspension. The sensitivity of carboxyfluorescein dye to changes in
fluorescence intensity with exposure to light was tested by exposing varied
concentrations to as much as five day’s exposure to ambient light. The results
shown in Figure 4.4 indicate the dye’s resistance to decay despite exposure,
reassuring us about any potential confounding effects of short term light
exposure on signal changes. Nonetheless, dye solutions were always stored
away from light in 4˚C.
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CF Fluorescence Intensity Decay with Exposure to light versus Time
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Figure 4.4 Stability of CF. The Decay of Varied Concentration of
Carboxyfluorescein.
At low concentrations fluorescence intensity is proportional to dye
concentration so encapsulation of dye can be calibrated by use of a standard
curve, as shown in Figure 4.5. At higher concentrations the relationship is not
linear and measured intensity will decrease with increased concentration due to
self quenching as shown in Figure 4.6. Entrapment of dye by niosomes was
measured by first disrupting the suspended niosomes with Triton X 100, a nonfluorescing detergent, and then measuring the fluorescence intensity of the dye
released by the vesicles into the suspending buffer solution70. Light and
fluorescence microscopy were also used to verify vesicle formation and
disruption.
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CF Concentration versus Fluorescence Intensity Calibration Curve
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Figure 4.5 Calibration Curve of CF. Carboxyfluorescein Molar Concentration vs.
Fluorescence Intensity
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Figure 4.6 Calibration Curve with a Wide Range of Concentrations.
Fluorescence Intensity with Respect to a Wide Range of Concentrations of
Carboxyfluorescein Dye.
4.2.2.3.

Vesicle Purification Materials and Methods

Niosome literature describes several methods of separating formed
vesicles from un-encapsulated hydrating solutions and unformed lipids33. Among
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them are gel exclusion chromatography, dialysis, centrifugation, and
ultracentrifugation. Gel exclusion chromatography was chosen as an appropriate
bench top method for this research. Gel exclusion chromatography (GEC) is
also referred to as size exclusion chromatography, and provides relatively rapid
separation of formed vesicles from unformed lipids and unencapsulated dye (or
drug). Dialysis is time consuming and only eliminates the free dye and not the
unformed lipids. Centrifugation provides only partial separation of unformed
lipids, created vesicle disruption, and has limited utility depending on vesicle
density. Ultracentrifugation was expensive and largely unavailable for our routine
experimentation.
4.2.2.3.1.

Gel Exclusion Chromatography

The theory behind GEC is straightforward. Gel filtration media is packed
into a column to form a packed bed. The medium is a porous matrix of spherical
particles, such as Sephadex G50, that are chemically and physically stable and
non reactive. Micrographs of hydrated Sephadex G50 beads at two
magnifications are shown in Figure 4.7. The packed bed is equilibrated by
flushing with a buffer solution (the mobile phase) such as phosphate buffered
saline (PBS). The liquid inside the matrix is referred to as the stationary phase.
The void volume refers to the volume of the column not taken up by the matrix.
Once a suspended sample is added to the gel matrix, buffer and sample move
through the column. Larger particles do not enter the pores of the gel matrix;
they move through the column at the same rate as the buffer, and elute within the
first column volume. Particles small enough to be caught up in the gel matrix
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pores elute later. The separation process takes place as one total column volume
of buffer passes through the gel filtration medium. Gel filtration is an isocratic
chromatography technique, meaning that separation is achieved without the use
of any kind of gradient.

Figure 4.7 Sephadex G50 Hydrated Beads. Left: 100x magnification, right:
200x.
According to the theory the particles or molecules will be separated
according to the Stokes radius of the particle. The equation for the Stokes radius
is M = αas where M is molecular weight, a is the Stokes radius, and s is the
sedimentation coefficient, α =

6πη 0 N
, where η0 is the viscosity of the solvent,
(1 − υ ρ )

υ is the partial specific volume of the particle, ρ is the density of the solvent, and
N is Avogadro’s number. Vesicle size can be calculated using the relationship
between the volumes of the system; k d =

Ve − V0
where V0 is the void volume, Ve
Vt − V0

is the elution volume, Vi is the pore volume, and Vt is the total volume, kd is then
the volume fraction of the stationary phase that is available to an eluting
species170.
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With GEC, hydrated samples were not only separated and purified, but
also the sample’s stability and entrapment over time could be evaluated by
studying the elution profile of the purified samples as they changed over time.
The plot in Figure 4.8 shows an overlay of two elution profiles, or
chromatograms, of two niosome suspensions of differing encapsulated PBS
concentrations. The abscissa is volume eluted and the ordinate represents the
UV absorbance (fluorescence is also measured) of the eluting volume. The first
peak is the signal from the niosomes which are eluted in the void volume, and
the second from the unencapsulated dye. As a suspension of vesicles
deteriorates over time, the first peak decreases and the dye released increases
the second peak. Theoretically, a newly purified stable suspension would have
no second peak. From the lack of a first peak signal in the 0.1M we discerned
that vesicles were not viable at the higher salt concentration due to the osmotic
gradient with the eluting buffer.

Figure 4.8 Chromatogram of Span 60 Niosomes of Varied PBS Concentrations.
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4.2.2.3.2.

Fluorescence Intensity

Fluorescent dyes are used as drug models commonly in research
because of the high sensitivity of fluorescence spectroscopy, which can be as
much as two orders of magnitude more sensitive than absorbance
spectroscopy82. Fluorescence spectroscopy uses changes in vibrational energy
levels of the molecule or substance being measured to assess levels of
fluorescence. The sample is excited by exposing it to a known quantity of
energy. By absorbing the energy in the form of a photon of light at a particular
wavelength the substance changes from a ground electronic state (low energy)
to a high frequency state (higher energy). Collisions between highly vibrating
molecules cause loss and emission of energy as they drop back down from the
excited high energy state to ground state and emit photons18,25. Instrumental
analysis of the energy absorbed and emitted at particular filter wavelengths
provides fluorescence intensity values that can be used to interpret sample
concentrations when compared to a standard curve (e.g. Figure 4.5.) Initial
fluorescence measurements were taken with a single measurement fluorescence
spectrophotometer, and later measurements were taken using a fluorescent plate
reader which allows for multiple readings to be taken at once. Figure 4.9 shows
the effect on vesicle disruption and subsequent release of dye from the vesicles
on the concentration of dye in the measuring container (cuvette or plate well).
The vessel on the left shows the dye concentration consistent within and outside
the formed vesicles after hydration, while the middle shows the vesicles
suspended in PBS with dye contained within them, and finally, the right vessel
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indicates the release of the dye from the vesicles into the suspending PBS. The
dye released from the disrupted vesicles creates the change in signal of the
fluorescence (FL) intensity.

Figure 4.9 Release of Dye from Niosomes.
4.2.2.3.3.

UV Absorbance

UV absorbance of materials is commonly used to measure concentration
in solutions of proteins and nucleic acids. The theory is straightforward;
materials which absorb ultraviolet light (wavelengths from 200-400 nm in the near
UV range171) have properties which obey the Beer-Lambert Law. The law is
expressed in different formulas shown below. The transmittance of light (T)
through the material is a ratio of the intensity of the incident light (I0) and the
intensity of the light after passing through it (I1).
T=

I0
I
4πk
= 10 − A = 10 −αlc , where A = log10 0 and α =
so that
I1
I1
λ

A = αlc

A is absorbance at a particular wavelength
l is the path length in cm
c is concentration in M
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k is the extinction coefficient for the material

λ is the wavelength of the light
So for a material with a known extinction coefficient, at a particular wavelength,
and a known path length, molar absorbance is proportional to
concentration148,172,173.
4.2.2.3.4.

Ultrasound

Energy can be added to order or to disrupt a system; in our niosome
development experiments we used ultrasound for both of those purposes.
Sound is the phenomenon we experience perceiving the propagation of pressure
waves through air or water. Mechanical vibrations create vibrating pressure
waves transferring energy from the source to the pressure waves and to anything
the waves contact. Audible (or acoustic) sound frequencies range from 20 Hz to
20KHz. Ultrasound waves are above 20KHz and outside the range of human
hearing141. Exposure of a biological membrane to ultrasound causes
sonoporation which is the temporary, non-destructive perforation of the cell
membrane. This transient state enhances permeability of therapeutic agents into
cells and tissues115. Similarly, the bilayer membrane structure of a self
assembly vesicle exhibits a temporary permeability with exposure to acoustic
forces174. Our suspensions of formed niosomes were exposed to ultrasound in a
bath sonicator to reduce lamellarity and size which is a common practice in
vesicle synthesis175. Experiments were conducted exposing different
formulations of niosomes to diagnostic US frequencies to test the potential of US
mediated drug release in vivo. Intensity levels of US exposure vary for different
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medical applications. Power levels greater than 10 W/cm2 are used in surgical
applications; therapeutic US ranges from 0.5-3 W/cm2, and diagnostic US ranges
from 0.1m W/cm2 to 0.5 W/cm2, 176.
4.2.2.4.

Equipment

Table 4.1. Equipment for Vesicle Development and Synthesis.
Equipment

Manufacturer

Model

Mass balance

Denver Instrument
Company
Buchi Laboratory,
Switzerland

A-250

Rotary evaporator

Bath sonicator
Particle sizing

Laboratory Supplies CO.,
INC
Particle Sizing Systems

Vaccuum Controller V-800
Buchi-Rotavapor R-200
Buchi-Heating Bath B-490
Buchi VacR V-500
Model G1125PIG
Accusizer 780ATM

Fluorescence
spectrophotometer
Fluorescence Plate
Reader
UV Microscope

Perkin Elmer

LS-3B

Biotek

Flx800

Lecia

Type 090-135.002

Inverted Fluorescence
Microscope

Olympus

IX71

Chromatography column

GE Healthcare
(Amersham Biosciences)
GE Healthcare
(Amersham Biosciences)

Superdex HiLoad XK 16/60

Fisher Scientific

Touch Mixer 231

Acuson

Aspen

Chromatography system

Vortex Mixer

ÄKTAprime

pH meter
Echocardiography
machine
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4.2.3. Methods
4.2.3.1.

Vesicle Synthesis

4.2.3.1.1.

Thin Film Hydration Techniques

Traditional thin film hydration techniques were first described in the
1960s6. In niosome synthesis this method involves dissolving surfactants,
cholesterol and, often, an electrostatic stabilizer (such as dicetyl phosphate) in a
non polar solvent, such as chloroform, and then evaporating the solvent and
forming a thin film of the dried chemicals on a vessel. Once all solvent is
removed, usually by employing a vacuum or nitrogen gas, the addition of an
aqueous solution hydrates the thin film. The hydrophobic/hydrophilic interactions
of the amphiphilic molecules when exposed to the aqueous environment cause
the self-assembly of lipid bilayer vesicles. As the hydrophobic tails orient
themselves together, they shield themselves from exposure to the water
molecules, and the hydrophilic head groups line up together inwardly and
outwardly exposed to the aqueous solution. Figure 4.1 (left) earlier in the text
shows a drawing of the orientation of the amphiphiles.
Initially several different formulations were investigated. While different
sorbitan ester surfactants were assessed, a consistent ratio of surfactant to
cholesterol to dicetyl phosphate was used throughout. The stability of vesicles
made using an equimolar ratio of surfactant to cholesterol with the addition of
13% dicetyl phosphate had already been well described177,178. A stable vesicle is
defined as one which maintains a consistent size and retains a constant level of
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encapsulant178. The first ‘generation’ of niosomes had lipid concentrations
approximately 10 mM. The concentration refers to the total lipid concentration in
the niosome suspension after GEC. It is calculated from the initial concentration
of lipids used to make thin films and taking into account the dilution of the
suspensions during GEC, and the process loss of vesicle as measured by
particle counts. As a general rule the dilution from post hydration to post GEC is
10x and the retention of formed vesicles is approximately 75%.
The lipids were dissolved in chloroform and aliquoted into 50 ml round
bottomed flasks. Early films were created by blowing a constant stream of
nitrogen gas at 5L/min. Later it was determined that residual chloroform could be
further reduced using a vacuum and so the vacuum pump of the rotary
evaporator was employed. Once the films dried they were hydrated by adding
either 0.01 M PBS, 5.0 mM CF, or 1.0-2.0 mM CR rotating for 1-2 hours in a
60ºC water bath. At regular intervals during hydration, the solutions were
agitated on a vortex mixer. Once complete, the solution was sonicated for 5-30
minutes in a bath sonicator at 80 KHz and 80 watts. Residual chloroform was
measured by mass balance. After 24 hours, the chloroform remaining was
measured to be less than 0.35% of original solvent by mass before hydration.
Table 4.2 shows the structures and descriptions of the surfactants investigated in
our research. The sorbitan monoesters are a family of alkyl esters of identical
head groups and varying alkyl chain length. Polyoxyethylene (PEO) sorbitan
monostearate (Tween 61) has the same structure as sorbitan monostearate, as
the names suggest, but includes multiple PEO polymer chains on its head group.
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The sorbitan monoester (Span) family was investigated because of its well
documented facility to form vesicles and its biocompatibility; they are widely used
in food, pharmaceutical and cosmetic industries93.
Table 4.2 Surfactant Structures and Properties.
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4.2.3.1.2.

GEC Purification

Once the hydration process is completed, 2 ml of 60˚C sample is injected
into the sample loop of the chromatography system. A preprogrammed elution
method is loaded from a PC. The sample is injected by the system into the
column from the sample loop through the injection port as 0.01M PBS is added
continuously at 1.0 ml/min. As the elution progresses, the system provides
information about temperature, pressure, conductivity, and UV absorbance at
280 nm. The elution method is split into phases where the eluted materials are
either captured or sent to waste; in the first phase the sample is introduced to the
column. Then the system resets the baseline UV reading to 0. For the first third
of the void volume the eluted material is discarded, after which the eluted
material containing the separated niosomes is captured in 2 ml fractions. Finally,
once the void volume has passed through the column, the eluted material is
again sent to waste, and the free dye is flushed from the column. The maximum
total volume of the XK 16/60 column is 124 ml. In order to flush completely after
a separation, the buffer is run for 2 total column volumes or 240 ml, although the
bed packing volume is usually about 100 ml, plus or minus 3-5%.
4.2.3.1.3.

UV Absorbance

The Akta prime system incorporated a UV sensor and automatically
generated chromatograms for each separation or assessment elution that was
run. Although UV is not as sensitive to changes in fluorescent signals as
fluorescence microscopy is, the curves provided useful run-by-run comparisons
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of different formulations. Unfortunately, the results did not prove as easily
quantifiable as those of the fluorescence reading because both the niosomes and
the fluorescent dye contained within them contributed to the signal at the
niosome elution peak as seen in Figure 4.10. The absorbance of niosomes at
280 nm which contain no absorbing solution can be explained by the presence of
double bonds and ring groups in the surfactants.
UV Absorbance vs Elution Time
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Figure 4.10 Intrinsic UV Absorbance of Niosomes. Tw-CC-CF represents a
niosome encapsulating CF dye, and Tw-CC-PBS represents a niosome
encapsulating PBS. The Tw-CC-CF curve has a second peak due to the
absorbance of free dye. PBS does not absorb UV at 280 nm.
4.2.3.1.4.

Niosomes of Differing Surfactant Components

Niosomes made from Span 20, Span 40, Span 60, or Tween 61 as the
surfactant component in 1:1:0.105 molar ratio with cholesterol and DCP were
made as described encapsulating a 5mM solution of CF. Table 4.3 shows the
masses of lipid components used. The encapsulation of the dye was measured
by disrupting the vesicles with Triton X 100 in a de-ionized water (DI) solution.
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Concentrations of entrapped dye were found by comparing the disrupted
niosome fluorescence intensity to a standard curve. Standard curves were
created for each type of dye and new dye solution. Particle sized distributions
were run for each of the formulations.
Table 4.3 Low Concentration Example of Vesicle Components.
Sp20

Surfactant mass(g)
SP40
Sp60
TW61
0.148
0.01
0.094

0.081

4.2.3.1.5.

Mass (g)
cholesterol
DCP
0.0437
0.00635
0.088
0.016
0.088
0.016
0.088
0.016

Total mols
2.37E-04
2.80E-04
4.90E-04
4.91E-04

Increased Lipid Concentrations

In order to increase the dye entrapment capacity of the niosomes, the lipid
concentrations were increased 7.5-10 fold, maintaining the original molar ratios
of the components. The GEC methods had to be adapted to the more
concentrated hydrated solution.
4.2.3.2.

Development of Tween 61-Span 60 Niosome

In order to conjugate a targeting moiety to a niosome, a linking agent had
to be conceived of that would either be attached or inserted into the niosomes
after they are formed, or to be incorporated within the membrane during
formation. The latter approach would not require an additional process step or
potentially affect vesicle stability. The surfactant Tween 61 shown in the right
side of Figure 4.12 (also seen in Table 4.2) is nearly identical in structure to Span
60 except for the additional incorporation of polyethylene branches on the
hydrophilic head group. The polyethylene oxide (PEO) groups on the polar head
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of Tween 61 surfactant potentially could be exploited as a linker for antibody
conjugation. This linkage is analogous to antibody coupling on the distal end of
PEG groups added to immunoliposomes 90,179.
4.2.3.2.1.

Tween-Span Mixed Formulations

Based on the results of the stability studies blends of the surfactant
component of the vesicles were examined. A combination of Span 60 and Tween
61 was selected with the aim of retaining the desirable qualities of Span 60
stability and retention, while maintaining the option to use the PEO polymer
groups from the Tween 61 on the membrane surface for antibody attachment.
We looked at combinations of small amounts of Tween 61 (0-10%) incorporated
with Span 60 while maintaining the 1:1:0.1 molar ratio of surfactant to cholesterol
to dicetyl phosphate. Table 4.4 shows masses of components used to make films
of the varied combinations of surfactants. For each formulation the retention of
dye over time of the vesicles was compared to the solely Span 60 surfactant
composition.
Table 4.4 Masses of Vesicle Components for Varied Tween 61 Surfactant
Percentages Ratios per Film.
% Tween

Tween 61 (g)

Span 60 (g)

Cholesterol (g)

DCP(g)

1.00%

0.00089

0.08826

0.10132

0.00752

3.25%

0.0028

0.08417

0.10333

0.00767

5.50%

0.00467

0.08027

0.10525

0.00781

7.75%

0.00643

0.07655

0.10707

0.00795

10.00%

0.00811

0.07300

0.10882

0.00808
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4.2.3.3.

Functionalization of Tween 61 with Cyanuric Chloride

Tween 61 was functionalized prior to niosome synthesis by activation of
the hydroxyl groups on the ends of the PEO chains. In the presence of
diisopropyl ethyl amine (DIPEA), Tween 61 and cyanuric chloride were incubated
in a nitrogen environment. The overall mechanism is shown in Figure 4.11. The
cyanuric chloride undergoes nucleophilic substitution binding to the terminal
hydroxyl group of a PEO chain on the Tween 61 molecule. The molar ratio of
Tween:CC:DIPEA was 1:0.8:2 90,180 and a 0.2 g/ml solution was made by
combining 1g Tween 61, 0.124 g CC, 0.274 ml DIPEA, and 5 ml chloroform. The
Tween 61 and chloroform were combined in a round bottom flask. Cyanuric
chloride was added and the DIPEA was withdrawn from a sealed flask using a
long sharp metal syringe tip and added directly into the mixture. The flask was
rotated in a nitrogen environment for 36 hours. The excess solution was stored
and remained stable at -4ºC for several months. The resulting functionalized
Tween-CC solution was added to the surfactants and lipids in chloroform prior to
forming a thin film.
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Figure 4.11 Tween 61 Cyanuric Chloride Linking Mechanism.
4.2.3.4.

Attachment and Verification of Antibody Conjugation

The GEC purified niosome solutions were adjusted to pH 8.8 by titrating 1

µl at a time of 1 M sodium hydroxide drop-wise while monitoring the pH. IgG
monoclonal antibodies (either fluorescently tagged Alexa-488 (AF)-IgGs or anti
CD44 IM7) were incubated with the niosomes at a concentration of and gently
shaken for 16 hours in the dark. At pH 8.8 the antibody binds to the cyanuric
chloride linker distal to the vesicle surface shown in Figure 4.12. Linking of
antibodies to either of the available chloride groups has equivalent potential
energy, however linking a subsequent antibody to the second available chloride
group would require much greater energy of activation, and is not favored when
other linkers on other molecules are available105. After antibody conjugation the
immunoniosome (IN) solution pH is restored to 7.4 using 0.1 M PBS.
Concentration of antibodies incubated was 5 µg protein /ml niosomes which is
equivalent to 2.78 µg protein/ µmol lipid. Concentration of total lipids in the post
GEC niosome solution is 1.8 mM, found by calculation from the original hydration
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concentration of 0.0144 M accounting for the 6 times dilution factor and particle
retention efficiency during GEC. Viable binding groups of Tween-CC linkage are
52% of the Tween component by calculation. This value is based on the reaction
molar ratio (1:0.8 of Tween:CC) and a published binding efficiency (65%) of the
reaction of CC with 1.2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine
polyethylene glycol (DPPE-PEG)24. The overall molar percentage of Tween in
the total lipid concentration of the niosomes was 4.76%, making the Tween-CC
linker 2.47% of total lipids, or 0.045 µmol Tween-CC/ml niosomes. This provides
2.68 * 1016 binding sites/ml niosomes. Antibody incubation of 5 µg antibodies/ml
of niosomes relates to a ratio of greater than 1300:1 Tween-CC binding sites to
antibodies.
In order to verify the efficacy of the linker chemistry and establish the
ability to bind antibodies to the surface of the vesicles, antibodies were
fluorescently tagged and incubated with non fluorescing niosomes for
conjugation. Fluorescent tagging of antibodies was done as described in the
protocol from a commercially available kit from Molecular Probes.

Figure 4.12 Antibody Conjugation.
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4.2.3.5.

Synovial Lining Cell Culture Methods

Primary cell cultures of bovine synoviocytes were used in niosome
incubation experiments. These cells were provided grown and already fixed by a
collaborator’s laboratory. The following description of the synoviocyte primary
culture comes from the resulting publication70. The synovial membranes were
harvested from the metacarpal phalangeal joints of 3 month old bovines. After
washing with phosphate buffered saline (PBS) the tissues were dispersed in
0.1% collagenase P in 4% bovine serum albumin (BSA). Isolated cells were
washed with PBS suspended in Dulbecco’s DMEM containing 10% fetal calf
serum at a concentration of 105 cells per ml. The cells were plated in Labtek 8
well micro-slides. Cells were allowed to attach overnight. The media was
removed, and the cells washed with PBS and fixed for 2 hours in Histochoice. A
subset of fixed cells was immuno-stained with IM7 using standard
immunohistochemical techniques.
4.2.3.6.

Immunoniosome Synovial Lining Cell Incubation Methods

The fixed cell layers were pre-incubated in 0.01 M PBS with 2% goat
serum with or without soluble IM7 antibody for 1 hour at room temperature prior
to incubation with immunoniosomes. Cells were rinsed with PBS and incubated
for 1 hour at 37 ºC with fluorescent niosomes with or without antibody
conjugation. The cells were well rinsed to remove unbound niosomes and
examined by fluorescent microscopy. Imaging of cells, cell nuclei, and INs was
done with an Olympus 1X71 inverted fluorescent microscope fitted with DAPI and
FITC (fluorescein isothiocyanate) filters allowing imaging of the green fluorescent
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niosomes and the blue stained cell nuclei. For a given image, a phase contrast
picture was captured, and then the light and filters were changed to fluorescent
mode to image the cell nuclei using the DAPI filter, and the FITC filter to image
the fluorescent niosomes bound to the cells. These images were captured and
combined using DP-BWR image analysis software to overlay them.
4.2.3.7.

Proof of Concept Cell Binding

To establish proof-of-concept cell binding, bovine synovial membrane
lining (SL) cells were plated at 1x 103 cells/mm2 on glass multi-well slides and
maintained in DMEM with 20% fetal bovine serum, until cells reached near 90%
confluence. The cell layers were washed and fixed for 24 hours in Histochoice
fixative and rewashed Hanks Buffered Saline (HBS). The fixed cell layers were
pre-incubated in PBS with 2% goat serum with or without soluble IM7 antibody
for 1 hour at room temperature to prevent non specific binding. Niosomes used
in SL cell studies encapsulated 5(6) carboxyrhodamine 110 (CR), a photobleaching resistant fluorescent dye. (Photobleaching is a loss of fluorescence
intensity due to exposure to intense light.) Cells were rinsed and incubated for 1
hour at 37 ºC with fluorescent niosomes or fluorescent niosomes derivatized with
IM7 (purified IgG). The cells were well rinsed to remove unbound niosomes and
were examined by fluorescent microscopy.
4.2.3.8.

Statistical Methods

Statistical differences in experimental values were calculated using
standard error of the mean (SEM) of at least three repeated measures. The
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formula for SEM is the ratio of the standard deviation of a data set divided by the
square root of the number of repeated measures, n. The standard deviation of a
set of measured values is defined as the square root of the variance. The
variance is the summed deviations of the measured values from the mean of
those values. If xi is an observation among n observations and x is the mean of
all the observations (the sum of all measured values divided by the number of
values measured) then the variance is:

s

2

St.Dev =

∑
=

n

i =1

∑

( xi − x ) 2

n −1

and the standard deviation is therefore;

n

2
(
x
−
x
)
i
i =1

n −1

.

The standard error of the mean is SEM =

St .Dev
n

. The SEM is represented

graphically as y-axis error bars in the graphs in this document. P-values are
used as another statistical method included in some of the reported data. In
hypothesis testing resulting data are evaluated as being different than the mean
of the measured values within a range of values. A p-value is defined as the
probability of a measure to be different than the mean of the measured values. If
a p-value of <0.001 is reported then there is less than 0.1% chance that there is
no difference in the means of the measured value versus the comparison value,
usually a control 181.
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4.2.4. Experimental Designs
4.2.4.1.

Vesicle Formulation Assessment

4.2.4.1.1.

Sorbitan Ester Formulations

Entrapment efficiency and membrane permeability of varied formulations
of niosomes were evaluated. Size reduction through sonication over time was
assessed in each formulation. Dye encapsulation capacity was assessed in
each formulation. Additionally the effect of sonication on vesicle size and count
was evaluated in the different Span compositions. The ability to accurately
evaluate the entrapment of dye by niosomes depends on the ability to completely
disrupt them.
4.2.4.1.2.

Tween-Span US Exposure Stability Study

Based on the results of the studies done on the different surfactant
candidates, niosome made from either Tween or Span 60 as the surfactant
component were evaluated for stability. The different vesicle formulations were
exposed to diagnostic ultrasound at 0, 5, 10 minutes using a transducer and an
Accuson Aspen echocardiography machine. Machine settings were kept
constant throughout the experiment with the frequency set to 3.5 MHz, the
dynamic range set to 70dB, and the initial gain set to 10 dB. During the
experiment the mechanical index of the instrument was varied. Mechanical index
(MI) is the ratio of the acoustic pressure over the square root of frequency.
Therefore max MI corresponds to a maximum acoustic pressure at a given
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frequency. The formula is MI =

P
f

where P is pressure in MPa, and f is

frequency in MHz. The spatial peak temporal average was 46 mW/cm2, and the
total absolute power was 65 mW. Fluorescence readings of the niosomes and
suspending fluid were obtained at 5 minute increments over 15 minutes of
ultrasound exposure. All vesicle characterization measurements were repeated
three times at each 5 minute time increment.
4.2.4.2. Polyoxyethylene Sorbitan Monostearate-Cyanuric Chloride
Linker Chemistry
The Tween-CC linkers were prepared as described and tested by first
attaching the fluorescently tagged IgG antibodies to non fluorescing niosomes
and assessing the vesicle morphology and fluorescence of the resulting
suspension, by GEC elution of the vesicle suspension. To further verify the
antibody binding to the niosomes, the post GEC purified AF-immunoniosomes
were examined with an Olympus 1X71 inverted fluorescent microscope.
Approximately 50 µl of immunoniosome suspension was pipetted onto a glass
microscope slide and viewed at 10 and 40x using a FITC filter to verify the
presence of fluorescent spherical particles. Fluorescent images where captured
using the Olympus DP-BSW software.
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4.3. Results
4.3.1. Sorbitan Ester Vesicle Formulations
4.3.1.1.

Results of the Varied Sorbitan Ester Formulations

The varied formulations were evaluated for entrapment by fluorescent
measurements and particle sizing. The entrapment of dye by each formulation
is shown in Figure 4.13. The Tween 61 niosome shows the greatest
encapsulation of dye, followed by Span 60. Entrapment decreases with
decreasing alkyl chain length. Figures 4.14 show that Span 60 forms the
greatest number of vesicles after hydration and retains the greatest amount of
dye after GEC.

Figure 4.13 Encapsulation of CF by Surfactant Type.
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Figure 4.14 Formation of Niosomes after Hydration by Surfactant Type.
In order to reduce vesicle size and lamellar number (number of bilayers)
bath sonication over a range of times was tested in the Span 20 and Span 40
niosomes after hydration and before GEC. The data in Figure 4.15 show that
vesicle size (number weight mean) decreases and vesicle count increases over
sonication time to an asymptotic value. The effect of sonication on the different
surfactants is not identical however. The concentration of particles greater than
0.5 µm (the detection limit of particle size analyzer) of the Span 20 vesicles
increases and reaches an asymptotic limit with sonication time while the
concentration of the Span 40 particles increase to a greater degree and
fluctuated more greatly. With both surfactants the mean particle diameter
decreases with sonication then levels out. This is to be expected since
sonication of vesicles reduces the number of bilayers in the vesicles and disrupts
aggregates182 and is directly seen in the micrograph shown in Figure 4.16 which
shows a light microscopy image of a PBS containing niosome sample on a
hemocytometer slide before and after sonication which was used to reduce and
unify particle size and lamellarity 183.
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Figure 4.17 shows the effect on sonication over the entire vesicle size
distribution. The curves show the particle size distribution of the unsonicated
versus sonicated vesicles of Span 60 niosomes. The size distribution clearly
shifts downward after sonication. Based on the results of the Span 20 and Span
40 niosomes it is assumed that a portion of the population of the Span 60
niosomes that are not seen in the post sonication distribution have dropped
below the detection limit of the PSS.

2

8.00E+08

1.5

6.00E+08

1

4.00E+08

0.5

2.00E+08

0
0

50

100

150

200

250

Particle
Counts/ml

Mean Particle
Size (um)

Span 20 and 40: Mean Vesicle Size and
Concentration with Sonication time

0.00E+00
300

time (sec)
Span 40: Mean Particle Size

Span 20: Mean Particle Size

Span 40: Particles/ml

Span 20: Particles/ml

Figure 4.15 The Effect of Sonication Time on Particle Size and Counts.

Figure 4.16 Sonication Effects. The Effect of Sonication on Vesicle Size
Distribution in Span 60 Niosomes.
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Figure 4.17 PSD Sonication Effects. The graph shows the shift in Particle Size
Distribution in a bath sonicated Span 60 nisome sample. The blue curve is the
size distribution of the sample before sonication, and the red curve represent the
distribution after sonication.
4.3.1.2.

Results of Ultrasound Exposure on Niosomes

Ultrasound exposure experiments were conducted on niosomes whose
surfactant component was either Tween 61 or Span 60, based on the results of
the earlier sorbitan ester experiments, establishing the two as the candidate
surfactants. Vesicle suspensions of the different formulations were monitored by
particle size distribution and fluorescence intensity measurements. The graphs
shown in Figure 4.18 represent the particle size distributions (PSD) of the control
and experimental samples over the duration of the experiment. On the left the
curves represent the PSDs of the Span 60 niosomes before (blue) and after (red)
US exposure. The right side of Figure 4.18 shows the same thing for the Tween
61 niosomes. It is clear by the closeness of the curves in each that the disruptive
effect of US on the formed particles was minimal. The particle counts are
expressed in numbers per ml of sample.
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Figure 4.18 PSDs with Respect to US Exposure. Left: Span 60 niosomes; right;
Tween 61 niosomes. For each blue is prior to US exposure, and red is after.
In Figure 4.19 the effect of US exposure time is seen to be significantly
greater in the Tween 61 niosomes than the Span 60 niosomes. Figure 4.20
indicates that release of dye is shown to increase with increased mechanical
index in Tween 61 niosomes, whereas the stability of the vesicles in the Span 60
with MI as shown in Figure 4.21. Taken all together, the stability of the Span 60
niosome and its ability to retain encapsulated materials is demonstrated to be
greater than that of the Tween 61. However, for controlled rapid release a
Tween 61 vesicle may be desirable.
% Increase in Free CF in Tween 61 and Span 60
Niosome Suspensions vs US Exposure Time at
MI=1.6
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Figure 4.19 The Effect of US Exposure Time on Release of CF. Error bars
represent SEM of n>=3.
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Figure 4.20 The Effect of MI on Released CF in a Tween 61 Niosome. Error bars
represent SEM of n>=3.
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Figure 4.21 The Effect of MI on Particle Retention in the Span 60 Niosomes.
Error bars represent SEM of n>=3.
4.3.2. Results of Surfactant Blending
Since the formulation of niosomes with Tween 61 as the sole surfactant
component were seen to be less stable than the Span 60 niosomes both
statically, and when stressed, the effect of the inclusion of a range of small molar
percentages of Tween 61 in a Span 60 niosome on vesicle entrapment capacity
and membrane stability was evaluated. This was measured by retention of
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entrapped dye over time at 4ºC in a PBS suspension. Although Tween 61
niosomes are reported to have a greater entrapment capacity 184 (which was
confirmed by the data shown in Figure 4.13), the observation was that niosomes
whose surfactant component was entirely composed of Tween 61 lost three
times more encapsulated dye relative to niosome formulations whose surfactant
component was purely Span 60 under static conditions holding cholesterol and
DCP molar ratios constant as shown in the tabulated values in the right side of
Figure 4.22. On the left side of the figure the data indicate that the inclusion of
up to 10% by mole of Tween 61 had no significant effect on the retention of dye
over the time examined. Statistical differences were judged by evaluating the
overlap of standard error of the mean graphically. Also, in order to increase the
entrapment capacity of the vesicles, and therefore increase potential drug
entrapment, the overall mass of lipids used was increased. The results of the
increase can be seen in the overlay chromatogram shown in Figure 4.23.
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Figure 4.22 The Retention of CF in Tween 61-Span 60 Niosomes. Left: graphical
depiction of the inclusion of 1-10% Tween. Right: Overall retention of dye in
various formulations in 15 or more days.
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Figure 4.23 Increased UV signal with Increased Lipid Concentration in Tw-CCCF Niosomes.

4.3.3. Results of Linking Chemistry Development
The verification of the linking chemistry was tested in two ways; first was
the assessment of the elution of PBS containing niosomes conjugated to
Alexafluor tagged antibodies. After incubation with the antibodies the niosomes
were purified using GEC which should have resulted in a suspension of non
fluorescing niosomes conjugated to fluorescent antibodies. That purified
suspension was eluted through a GEC column and measured by UV absorbance
at a wavelength of 280 nm. Figure 4.24 shows a signal in the niosome elution
volume. There is also a very slight signal in the antibody elution volume (before
120 ml) which show a few free AF antibodies; the protein and the bound dye
would both contribute to the signal at that wavelength.
This indicates that there are negligible numbers of free antibodies in the
solution and demonstrates successful attachment of Alexa Fluor tagged IgGs to
PBS containing niosomes.
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Secondly, the niosome suspension was imaged using fluorescence
microscopy as seen in Figure 4.25. Further confirmation of the conjugation of AF
antibodies was evident when fluorescent spheres were evident under a
fluorescent microscope using a FITC filter. The presence of distinct and discrete
spherical fluorescent particles confirms the conjugation of the fluorescent
antibodies to the non fluorescing niosomes and the efficacy of the linker to attach
the antibodies to the surface of the niosome membrane. The discrete fluorescent
spheres appear to be of the same size and relative size distribution of niosomes.
These two independent measures indicate successful antibody conjugation of the
AF antibodies to non fluorescing niosomes.

Figure 4.24 Elution of IN with Fluorescent Antibodies.
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Figure 4.25 Fluorescent micrograph of IN with Fluorescent Antibodies.
The effect of the Tween-CC linker on the 10% Tween 61 niosome was
evaluated over 22 days. Figure 4.26 shows an overlay of four separate elutions
of the same sample of post-GEC 10%Tween 61 niosomes. Due to slight
differences in column packing and suspension injection the chromatograms do
not line up perfectly, but do indicate very little variation in the suspension over
time.
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Stability of 10%Tw-CC-CR Niosome Suspensions
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Figure 4.26 Stability of the 10%Tw-CC-CR Post GEC Niosome.
4.3.4. Binding of Immunoniosomes to Synovial Lining Cells
The binding of the immunoniosomes to the target antigen in a fixed cell
model was confirmed as follows. The fluorescent and light micrographs shown in
Figure 4.27 demonstrate the specificity and selectivity of immunoniosome binding
to target antigens. The upper micrograph figures of cells (A, C, and E)
correspond exactly to the fluorescent micrographs below them (B, D, and F).
Parts A and B of Figure 4.27 correspond to the cells incubated with IM7 tagged
niosomes and show binding of the immuno-niosomes evident by the bright
spherical shapes attached at cell processes and cell membranes. Whereas the
cells pre-incubated with free IM7, shown in C and D, do not show the small
spherical attachments due to blocking of the targeted binding sites. This
demonstrates the targeting selectivity of antibody antigen binding. In parts E and
F, cells have been incubated with unconjugated niosomes. Additionally, the
absence of binding in the cells incubated with untagged niosomes, parts E and F,
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demonstrates the specificity. In all of the fluorescence images some
autofluorescence of cells is evident, but clearly distinct from the brighter point-like
images of the fluorescent niosomes. In the left hand side of Figure 4.28, IHC
staining techniques show the CD44 expression at the cell processes and at the
cell membranes as indicated by the red arrows. Correspondingly, binding of
green fluorescent INs in the right hand side of Figure 4.28 is seen at cell
processes and membranes.

Figure 4.27 Experimental and Control Images of Synovial Lining Cells. The
upper slides (A), (C), and (E) show contrast micrographs and the lower slides
(B), (D), and (F) are the corresponding fluorescent micrographs of those above
them captured using a FITC filter. (A) and (B) show SL cells incubated with IM7tagged niosomes containing 1 mM CR dye. (C) and (D) are SL cells preincubated with free IM7. (E) and (F) are cells incubated with untargeted
niosomes (no IM7).
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Figure 4.28 Synovial Lining Cells. Left: IHC stained for CD 44 with nuclear
counterstaining. Arrows indicate CD44 expressed on cell processes. (40 x
magnification Olympus BH 2)
4.4. Discussion
The results of the experiments to this point confirm the capacity to develop
monoclonal antibody conjugated niosomes targeted to specific cell receptors.
The investigation of members of sorbitan ester family as the candidate surfactant
in our vesicle revealed that Span 60 had the best combination of entrapment
capacity, stability and retention versus the others studied. However, since the
polyoxyethylene polymers on the Tween 61 head group extend distal to the
surface of the formed niosome they would provide ideal linking moieties for
antibody conjugation. Blending the surfactants in order to retain the desired
properties of each surfactant was conceived and the results showed that the
inclusion of as much as 10% of Tween 61 within a niosome composed of Span
60 in the surfactant component maintained the desirable stability and retention
properties of the ‘purely’ Span 60 niosome. Sorbitan monostearate based
niosomes can be functionalized through inclusion of a cyanuric chloride
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derivatized polyoxyethylene monostearate to conjugate monoclonal IgG
antibodies to the vesicle surfaces without requiring derivatization of the antibody.
The coupling of IgG antibodies to formed and purified vesicles was
verified. The resulting ‘immunoniosome’ was shown to bind to target antigens in
fixed cells. In the fixed SL cell model targeting shows high selectivity and
specificity demonstrated by the lack of IN binding to the target antigen when
blocked with free antibodies specific to the antigen, and also the inability of
untargeted (non antibody conjugated) niosomes to bind to cells. The results of
the fixed cell SL binding studies demonstrated that further investigations were
warranted to investigate binding and then uptake by inflamed endothelial cells in
vitro and in vivo. The implications for therapeutic treatment of inflammatory
diseases is significant not only in the capacity to target chemical therapy to
affected tissues but also to block receptors of inflammatory pathways and to
interrupt the perpetuating effect of the process 178. Also, since the attachment of
antibodies is independent of the type and generic to any IgG antibody, the
system’s therapeutic targeting is flexible and may include more than one
targeting vector if desired.
In order to pursue live cell uptake experiments the size and particle
distribution of INs would have to be addressed. Size reduction protocols using
extrusion, and monitored by sub-micron particle sizing, would modify and verify
vesicles of size conducive to cellular uptake177. Additionally, measurement of
optimal antibody coating density would need to be pursued. By using activated
fixed aortic endothelial cells (an appropriate model for vascular inflammatory
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drug uptake studies) optimizations of the drug targeting system could be
conducted prior to pursuing live cell uptake studies. In liposome applications, as
few as tens of antibodies or antibody fragments 185 conjugated per vesicle have
shown binding and cellular uptake, necessitating the optimization of our immunoconjugation.
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5. Fixed Endothelial Cell and Immunoniosome Binding Studies
5.1. Background
5.1.1. Endothelial Cells Antibody-Targeted Drug Delivery
Endothelial cells are a type of epithelial cell; they are single-layer simple
squamous epithelial cells which line blood vessels and are therefore the
mediating layer between the blood stream and the tissue that they line. Varying
targeting drug delivery strategies have been studied using activated endothelial
cells expressing adhesion molecules. Different targeting schemes have been
reviewed and/or studied including cardiovascular liposome targeting,
nanomedicine, pulmonary targeting of liposomes with antioxidants and antithrombotics, and enzymatic therapeutics, also using polymeric nanocarriers.
Vesicular or nanocarrier cardiovascular targeting strategies frequently include an
endothelial cell model with a target adhesion molecule and the corresponding
antigen vector. In the studies described in this section 10%Tween-CC niosomes
conjugated with an anti-CD44 antibody were targeted to bovine aortic endothelial
cells (BAECs).
The aim was to verify and quantify binding of the INs to activated BAECS
under differing experimental variables such as incubation time, concentration of
lipid and antibody coating. Throughout these BAEC fixed cell binding
experiments the niosome abbreviation IN refers to the formulation defined in Part
4, the blended surfactant niosome with the Tween 61-cyanuric chloride linker,
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containing the photobleaching resistant dye, carboxyrhodamine (CR), conjugated
to the anti-CD44 antibody, IM7.
5.2. Materials and Methods
5.2.1. Materials and Chemicals
Included in this list are the materials and chemicals new to this phase of
the project that were not included in Section 4.2.2.1. Cambrex endothelial cell
basal media (EBM), bovine calf serum, penicillin-streptomycin, 0.05% (w/v)
Trypsin-EDTA solution, 99% HEPES sodium salt, and 100% ethanol all came
from Fisher Scientific, as did all the pipettes, flasks, filters, syringes, and
centrifuge tubes. The secondary antibodies used for IHC came from Sigma
Chemical as did the Tris buffer, and sodium acetate. Cryo-preserved endothelial
cells (BAEC) came from Clonetics, Inc. The IHC ABC staining kit (Cat# PK 7200)
came from Vector labs, as did the diamino benzidine (DAB) substrate kit
(SK4100), the diamidino-2-phenylindole (DAPI) nuclear mounting stain, and the
hard set mounting media. The potassium ferricyanide and uranyl acetate were a
kind gift from Ed Haller from the Pathology Department of USF Health. Osmium
tetroxide and gelatin came from USF Health Core facilities.
5.2.2. Methods
5.2.2.1.

Endothelial Cell Culture

Endothelial cells were grown using classical sterile techniques in 25cm2
sized cell culture flasks in endothelial basal media supplemented with 10% fetal
calf serum, 1% penicillin-streptomycin and 1% non essential amino acids. Cryo-
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preserved cells were started on flasks that had been coated with collagen to
encourage adhesion. Cell growth media was changed every 2-3 days. The cells
were cultured to a confluent monolayer and then sub-cultured into 8 well microslides for incubation with INs and subsequent imaging. Cells were sub-cultured
by releasing their adherence from flasks with the enzyme trypsin, which is a
serine protease of the pancreas which breaks down peptide bonds of the
carboxyl groups of amino acids arginine and lysine. The commercially available,
purified form of trypsin is used commonly in cell culture to release cells from
culture vessel surfaces.
To release the cells from the flasks, first the growth media was removed
by pipette, and then the cells were rinsed several times with 37˚C 0.01 M PBS to
eliminate the anti-trypsin agents present in the endothelial media. Next 2 ml of
0.05% trypsin was added to the flask and incubated at 37˚C for 5-10 minutes.
Release of cells from the surface was monitored using a phase contrast
microscope. Once the cells were released, the vessel wall was washed further
with PBS, and the suspended cells were centrifuged for 3-4 minutes at 3000 rpm.
The trypsin and PBS were removed by pipette from the resulting pellet of cells
which were re-suspended in growth media and 400 µl aliquots were added to the
individual wells of the micro-slides.
The cells grew to near confluence in 1-2 days. A day prior to incubation
with INs, fresh media supplemented with 7 ng/ml TNF-α (an inflammatory
cytokine whose role in adhesion molecule expression is described in Section 2.3)
was added to the culture to activate the cells and induce the expression of
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adhesion molecule CD44. Prior to incubation with INs the cells were fixed
overnight with either Histochoice, for IHC staining, or with paraformadehyde, for
fluorescence imaging.
5.2.2.1.1.

Gelatin Coating Procedure

Coating of culture vessels with either collagen, gelatin or fibronectin helps
encourage primary or cryo-preserved endothelial cells to proliferate in initial
culturing. A 2% by weight solution of solid gelatin was prepared in pyrogen free
deionized (DI) water for flask coating. The DI was heated to 80°C and the
gelatin was dissolved in the water. The dissolved gelatin and water were kept at
the increased temperature for 10 minutes and then the solution was cooled to
about 30˚C and filtered with a 0.22 µm syringe filter. If the solution is allowed to
cool too much then filtration becomes very difficult. Then 1.5-2.0 ml of the
solution was added to 25 cm2 culture flasks and incubated at 37˚C for 4 hours or
longer. The excess solution was drawn off with a pipette and discarded while
working under the sterile hood. Unused gelatin solution can be stored at 4˚C for
later use.
5.2.2.2.

Cell Fixation

Fixation of cells stabilizes the structure and allows solvents to penetrate
the plasma membrane. Paraformaldehyde (PF), which does not fix by cross
linking, has been identified as being the best preservative of cell structures.
Because PF does not induce autofluorescence it is also a preferred fixative in
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fluorescent microscopy applications. Typically concentrations of 2-4% in buffer
solution are reported for cell fixation.
5.2.2.3.

Immunohistochemical Staining

Immunohistochemistry (IHC) is used to demonstrate the presence and
location of antigens in cells or tissues. There are several factors which
determine how well the antigen will be detected, chief among them the density
and dispersity of the antigens presented on the cells. The fixative type can have
an effect on antibody-antigen binding if the cells structure is greatly changed in
the fixation process. Detection is also impaired due to the antigen signal versus
non specific background binding. This can be offset by using a blocking buffer,
usually a non specific protein or serum of the antibody host. The specificity of
the antibody used is also important. Monoclonal antibodies give the most
specific binding and lowest background, especially when used after a binding
buffer treatment.
A subset of the experimental cells which had been TNF-α activated but
not incubated with INs underwent IHC staining to verify the expression of the
target antigen, CD44. The commercially available kit from Vector Labs that was
used employs an immunoperoxidase procedure with avidin-biotin binding.
Avadin is a 68 kDa glycoprotein that has a very high affinity (1015/M) to bind to
the smaller biotin molecule. This affinity makes the binding essentially
irreversible, and is 106 times greater than any antibody-antigen association. The
kit is purchased specific to the cell type (e.g. mouse IgG) and primary antibody
employed, and the primary antibody is specific to the target antigen to be
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detected. The general idea is that the primary antibody will adhere to the antigen
that you wish to identify, and a secondary biotinylated antibody will adhere to the
primary antibody. The biotin groups on the secondary antibody provide binding
sites for the avidin biotinylated enzyme complex containing horseradish
peroxidase. Cell nuclei were counterstained with diaminobenzidine (DAB) which
provided an orientation of the expressed antigen relative to the rest of the cell.
The staining procedure was carried out according to the instructions of the
manufacturer.
5.2.3. Incubation Experiments
5.2.3.1.

Design of Experiments

The aim of the experiments was to assess the ability to bind the
10%Tween-CC-CR niosome conjugated to IM7 with activated endothelial cells,
and to examine the effect of experimental and design variables on binding.
Variables examined, shown in Table 5.1, were incubation time, lipid
concentration, and antibody coating density. Each variable was given an
individual eight well microslide. Whenever PBS is mentioned the concentration
was 0.01M unless otherwise indicated.
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Table 5.1 Experimental Variables of BAEC-IN Binding Experiments.
Concentration of IgG

Lipid Conc.

Incubation

(ug/ml)

(mM)

Time (hours)

5.00

1.0125 mM

4

0.50

5.0625 mM

2

0.05

10.125 mM

1

Control niosomes (non INs)

10.125 mM

Control Abs (pre IM7 post IN)

10.125 mM

After incubation the cells were imaged with fluorescence microscopy to
ascertain niosome binding relative to cell binding density by measuring the
fluorescence intensity of the green bound niosomes and the blue DAPI stained
cell nuclei. A custom made MatlabTM analysis program described in Section
5.2.4.3 allowed for the analysis of the fluorescent images and quantify the
fluorescence intensity of binding relative to cell density. The first set of
experiments were done at an antibody concentration of 5.0 µg/ml antibody, and
then the other antibody densities were examined with optimal variables found in
the time and lipid concentration studies.
In order to verify binding independent of the fluorescent techniques a
subset of IN incubated BAECs were separately fixed and coated for imaging by
scanning electron microscopy (SEM).
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5.2.4. Description of Methods
5.2.4.1.

Incubation of Niosomes with Endothelial Cells

Cells grown in 8 well micro-slides were fixed with 4% paraformaldehyde
diluted in 0.01 M PBS at 4˚C overnight. Prior to incubation the fixative was rinsed
from cells three times with PBS. The cells were pre-incubated with 2% goat
serum in PBS for 1 hour at 37˚C to prevent non specific protein interactions and
then were rinsed three times with PBS. The niosomes were added to the cells
and incubated for the designated time. After the IN-cell incubation the cells were
rinsed three times with PBS and a drop of DAPI nuclear stain was added to each
well. After staining, the wells were removed from the slide and the mounting
media was added drop-wise to the slide and a cover slip was placed over the
cells and was left to dry before imaging.
5.2.4.2.

Fluorescent Microscopy Imaging of Incubated Cells

Fluorescent and phase contrast imaging of cells, cell nuclei, and INs was
done as described in Section 4.3.2.6.

Each treatment variable was imaged

multiple times (3-5) in multiple wells (2-4) at 20x and 40x magnification.
5.2.4.3.

Image Analysis

Overlays of fluorescent and phase contrast images were created as
described in Section 4.2.3.6 in order to visualize binding. In order to quantify
binding the images were analyzed using a customized image analysis Matlab™
(Mathworks) program. Example output and compiled data from the program is
included in Appendix D. Essentially a graphic user interface was developed in
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which the user first is prompted to import the fluorescent image of the nuclei as
shown in Figure 5.1 left. The image includes a scale bar, and the program uses
it for calibration. The right side of Figure 5.1 demonstrates the next step as the
user is prompted to crop the image (if desired), before setting a threshold value
of image intensity. Setting the threshold allows the user to compensate for
variability in image clarity and intensity and can be an iterative process with the
desired outcome being the identification of the individual nuclei and the removal
of background noise, as shown by the image in Figure 5.2. Once the threshold is
established, the nuclei are individually identified and counted, shown in the right
side of Figure 5.2, by running Process 1. Process 1 measures the area of each
identified nuclei and creates minimum, maximum, and average values for the
group, and then, using those values, it evaluates whether each one is a single or
greater count (Figure 5.3) and then sums the group.

Figure 5.1 Matlab Program Importing and Cropping. Left: Importing of the
fluorescent nuclei image. Right: The original image is cropped for analysis.
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Figure 5.2 Matlab Program Image Sorting. Left: Setting the threshold in process
1. Right: The identified objects are sorted and counted.

Figure 5.3 Matlab Program Image Analysis.
The fluorescent image of the niosomes which correspond to the same field
as the previously imported nuclei image was imported (Figure 5.4 left). The
same process of setting a threshold was repeated. Process 2 sorts the niosome
images. Once the overall process was finished the program has calculated the
number of cells, the total area of cell nuclei and the cell density, the niosome
count, and created an overlay image of the two processed fluorescent images as
seen in Figure 5.4 right. The discrete counting of niosomes was amended to
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calculating fluorescent area of the niosomes instead, reasons for which will be
discussed in greater detail in the results section, Section 5.3.1.

Figure 5.4 Matlab Program Fluorescent Nuclei and IN Overlay. Left: Importing
the IN fluorescent images. Right: Overlay of processed images
5.2.4.4.

Scanning Electron Microscopy

Scanning electron microscopy was used to verify the binding of niosomes
to cells independent of the fluorescent measures, and to assess the patterns of
surface binding of niosomes to endothelial cells. The cells were grown on square
glass cover slips to allow for fixation and metal coating prior to SEM imaging.
Before incubation with INs, the BAECs were rinsed with 37˚ C PBS several times
to remove serum proteins, and then were fixed with 2.5% glutaraldehyde in PBS
overnight at 4˚C. The fixed cells were rinsed three times with PBS (cells may be
stored at 4˚C in PBS at this point, if required). Cells were then incubated with
niosomes at 37˚C for the designated times and rinsed with PBS three times
again afterwards. A 1.5% potassium ferricyanide-1% osmium tetroxide solution
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was prepared under a fume hood in DI and added to the cells to incubate in the
dark for 1 hour1.
Once the osmium fixation step was completed, the cells were rinsed three
times with a 0.1 M sodium acetate buffer. The lipids of the niosome membranes
were fixed with the addition of a 1.5% uranyl acetate solution in 0.1 M Tris buffer
for an hour. Before the dehydration began, the fixative was rinsed three times
with sodium acetate buffer. Dehydration was done in a graded series for 5
minutes per treatment starting with 30% ethanol, then 70%, 95%, and 100%
twice. Once the cells were dehydrated, they were substituted with a 1:1
preparation of hexamethyldisilazane (HMDS) and 100% ethanol for five minutes
followed by two five minute treatments of pure HMDS. The coverslips of fixed
cells and niosomes were dried under the fume hood. After this fixation process
they were mounted on stubs and sputter coated by Ed Haller in the USF Health
core facilities lab. The SEM imaging was done with Betty Loorman of the
Biological Electron Microscope Facility of the Biology Department at USF on a
JOEL JSM 35 scanning electron microscope.

1

Extreme care must be taken working with these strong fixatives which

can rapidly fix mucous membranes at low concentrations, and all contact with
liquid and fumes must be avoided. Dispose of chemicals in a dedicated OsO4
container.
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5.3. Results
5.3.1. Endothelial Cell-Immunoniosome Images
5.3.1.1.

Fluorescent Micrographs

Figure 5.5 shows the IHC stained BAECs with nuclear counterstain after
activation with TNF-α. White arrows indicate expressed CD44 on cell surfaces
and processes. Correspondingly, the two images in Figure 5.6 shows the green
fluorescent niosomes attached to the cell processes and surfaces at different
magnifications. Both images represent INs conjugated to 5µg/ml IM7 antibodies
and incubated for 2 hours prior to imaging.

Figure 5.5 Immunohistochemical stain for CD44.

Figure 5.6 Fluorescent and Contrast Overlay of BAECs and INs. Left: 40x
magnification. Right 20x.
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5.3.1.2.

Scanning Electron Micrograph Images

The left side of the SEM image shown in Figure 5.7 shows fixed cells
incubated with INs, and the right side is a control of the same group of cells that
were not incubated with INs. The vesicles seen on the cell surface of the left
image are spherical and appear to be approximately the same size as the post
GEC niosomes. The comparison was made by matching the vesicles to the 1

µm white line above the 10 µm scale line as shown.

Figure 5.7 Scanning Electron Micrographs of BAECs. Left: INs bound to cell
surfaces. Right: Control.
The graph in the left side of Figure 5.8 shows the effect of lipid
concentration on relative binding density at different incubation times. The graph
in the right side of Figure 5.8 displays the same data relative to incubation time at
the different lipid concentrations, and the control data shown there reflect the
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incubation of non targeted niosomes (without conjugated antibodies) at the
maximum lipid concentration.
Figure 5.9 shows the affect of antibody concentration on the relative
binding of INs to fixed BAECs. In all graphs the error bars represent the
standard error of the mean with n>=3.
Binding Density vs. Incubation Time
40

Conc= 1.0125 mM
Conc= 5.0625 mM
Conc= 10.125 mM

35

Controls Conc=10.125 mM

30

30

Relative Binding Density

Relative Binding Density

35

Cell-Niosome Binding Density vs Concentration
40

25
20
15

25

1 hour incubation
2 hour incubation

20

4 hour incubation
15

10

10

5

5
0

0
1

2

0

4

2

4

6

8

10

Concentration of lipids (mM)

Time (hr)

Figure 5.8 Binding Density with Respect to Time and Concentration. Left:
Binding density with respect to lipid concentration at different incubation times.
Right: Binding with respect to time at different lipid concentrations as compared
to controls. All p<0.01 as compared to controls.

Figure 5.9 Binding Density with Respect to Antibody Concentration. Graph
shows relative binding density at 1 and 2 hour incubation times.
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5.4. Discussion
The aim of the experiments was to establish definitively that the drug
targeting system would bind to fixed endothelial cells at the target antigen. The
IHC staining of Figure 5.5 indicates that CD44 was expressed on the fixed bovine
endothelial cells at the cell processes and surface. The two fluorescent
micrograph-overlay images shown in Figure 5.6 indicate binding of the vesicles in
those regions. Furthermore, examination of the SEM images in Figure 5.7 shows
that vesicles of the right size and shape were observed bound to cell surfaces
and that similarly shaped features were not observed in the control image. The
binding of the vesicles to cell surfaces is observed in both cases to be nonhomogeneous, and the accumulation of multiple vesicles concentrated in small
areas as compared to relatively sparse binding in other areas led us to believe
that discrete counting of bound INs by fluorescent measures would be
inaccurate. The original MatlabTM routine created a ratio of discrete counts of cell
nuclei to discrete counts of niosomes. Once the SEM data revealed that
niosomes may be bound closely together in groups making individual counting
unlikely, the analysis was reconfigured to measure fluorescence intensity by area
of binding and the data are shown to reflect binding area relative to controls.
The graph in Figure 5.8 left shows that the binding of INs at 1hour
incubation time is independent of concentration of lipids. The binding intensity at
1 hour corresponded exactly to what was observed in the synovial lining studies.
At increased incubation times the binding increased at the 5 mM lipid
concentration, but little increased binding was observed in either an increase in
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incubation time or in an increase in lipid concentration. The graph of Figure 5.8
right shows the same data with the controls included to clarify the effect of time
on binding density with respect to each of the lipid concentrations. The control
data at each incubation time represent non-immunoniosomes incubated at the
maximum lipid concentration.
Immunoniosome binding relative to different coatings of antibody
concentrations is shown in Figure 5.9. With increasing antibody concentrations,
increased relative binding was observed, although at the lower antibody
concentrations there appeared to be no variation in binding at 4 hours. Binding
of INs at 1 hour was not studied based on the previous data. Additional testing of
binding relative to concentrations of antibodies between 1-5 µg/ml may yield an
optimum point.
In conclusion, the results shown indicate that INs bind to activated fixed
endothelial cells specifically and in a non homogeneous pattern. The binding
relative to time and lipid concentration increased to a limiting value but antibody
concentration did not for the concentrations studied. For the treatments studied,
5 mM at 2 hours appears to be optimum in binding density while conserving
material. Further studies will be conducted to investigate uptake up by live
endothelial cells in vitro to prepare for in vivo animal studies. Section 6
describes the uptake of IM7 conjugated immunoniosomes in live cells.
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6. Live Endothelial Cell Uptake Studies
6.1. Background
6.1.1. Live Endothelial Cells in Targeted Drug Delivery
Live endothelial cells have been used as a cell model for testing drug
targeting efficacy for many applications including immunoliposomes targeting
inflammation and for delivering anti-thrombolytics, and echogenic
immunoliposomes for imaging and targeting. The cells have been used in flow
experiments for tumor targeting, using antibody fragments, and to address
targeting of quiescent versus proliferating cells. Uptake of antibody targeted drug
delivery vesicles is highly dependent on the target antigen, as previously
described (Section 2.3). In order to further investigate the IM7 conjugated
immunoniosome as an effective treatment against inflammation the uptake of the
vesicles into cells needed to be verified using live cells. Additionally, since
accumulation, permeability, and uptake of vesicle by cells has been well
established as being size dependent the size of the vesicles would need to be
reduced. A study involving liposomes suggests that the preferential size for
uptake by atherosclerotic lesions is 200 nm. Size reduction of niosomes has
been reviewed115 and includes probe sonication, extrusion through polycarbonate
filters, micro-fluidization, and high pressure homogenization. Extrusion gave the
best size control while maintaining comparable levels of encapsulation.
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Microscopic methods used for investigating IN uptake by activated BAECs
were confocal microscopy and transmission electron microscopy (TEM). With
confocal microscopy fluorescent images are captured in multiple x-y planes in a z
direction. The result provides three-dimensional information about cellular
uptake of a fluorescent vesicle. TEM provides very high magnification and
resolution because the energy source from which the image is formed is a beam
of electrons rather than light, which has a resulting wavelength (in a vacuum and
at a small angle) 3 orders of magnitude lower than that of light.
6.1.2. Dynamic Light Scattering
Dynamic Light Scattering (DLS), also referred to as photon correlation
spectroscopy, is used widely to measure the size and distribution of dispersed
particles by measuring the changes in laser light projected through the particles.
The random movement of small particles in a suspension is called Brownian
motion, and is caused as particles collide with molecules from their surroundings
and diffuse randomly. When polychromatic light hits small suspended particles,
the light is scattered in many directions; this is referred to as Raleigh scattering.
However, when monochromatic light is shined into a solution of particles
undergoing Brownian motion, the light hitting the moving particles undergoes a
Doppler shift when changing wavelength, which can be measured. The change
in wavelength is related to the size of the particle that the light hit.
Particles undergoing Brownian motion travel at different speeds related to
their size; smaller particles move faster than larger ones. This relationship is
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defined by the Stokes-Einstein equation. First, the Einstein relation describes
diffusion of particles:

D = µ p k B T ; where D is the diffusion constant, µp is the mobility of the
particles, kB is Boltzmann’s constant (a physical constant which relates energy
and temperature;1.38 x 10 -23 J/K) , and T is the temperature in K. Under
conditions of low Reynolds number (the ratio of inertial to viscous forces) the
mobility is related inversely to the drag coefficient, γ, where under Stokes Law,
spherical particles of a radius r:

γ = 6πηr ; η is the viscosity of the media in which the particle is
dispersed. Therefore taken together, the Stokes-Einstein equation becomes

D=

k BT
Diffusion coefficient units are in m2/s . The hydrodynamic
6πηr

radius is then found by:

rH =

k BT
.
6πηD

Through these relations, given viscosity and absorption of suspending
media, and the temperature of system, the DLS system algorithms measure
particle size and/or molecular weight of a suspension through the use of a digital
correlator. The correlator measures how closely two signals are over a period of
time. Correlation is a statistical technique for reducing noise and finding a real
signal within it; it measures the degree by which a signal is not random when it
would appear to be. The second order equation is:
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G (τ ) =

I (t0 ) I (t0 + τ )
I (t∞ ) 2

where the function relates the product of the

intensity at t0 by the intensity at t0 increased by some value τ as a ratio to the
square of the intensity overall squared.
6.1.3. Monoclonal Antibody Fragments
Another important consideration in effective targeted drug delivery is the
persistence of the system within the bloodstream. Vesicle encapsulation of drugs
has been shown to increase circulation time, improve bio-distribution, and
prolong therapeutic plasma levels in vivo versus free drug administrations. If the
drug delivery vesicle or targeting vector provokes an immune response within the
body and subsequent rapid clearance from the blood stream there may not be
sufficient time or payload of drug delivered to be efficacious. Concern about the
rapid and increasing clearance of immunoliposomes in vivo with subsequent
intravenous injections was solved when antibody fragments were substituted for
whole antibodies.
While antibodies have been discussed in earlier sections, a description of
the physical structure was not given in detail. An antibody is a glycoprotein of
molecular weight 150 kDa which is made up of two general types of polypeptide
chains, two heavy chains and two light chains. The light chains are about 25 kDa
each, and each heavy chain is about 50 kDa. There are five subcategorizes of
antibodies, IgA, IgE, IgD, IgM, and IgG. These differ by their heavy chains types
and structural makeup. The chains are held together by a series of disulfide
bonds. Figure 6.1 shows the general structure of an antibody with respect to the
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different chains. An IgG, which is the subgroup of interest for this research, is
composed of either of two types of light chains, κ or λ, and the γ1 heavy chains,
which designate the subgroup.
The antigen binding (variable) region is indicated at the top of Figure 6.1,
and is specific to the exact antigen to which the antibody binds. The regions
below are conserved, and consistent by antibody type. The area between them
is referred to as the hinge region. Overall above the hinge is referred to as the
F(ab’)2, and below the Fc region. The immune response to the
immunoliposomes was provoked by the Fc region of the antibody and was
negated when Fab fragments were used. As Figure 6.1 indicates, fragmentation
of antibodies can include a single or a coupled Fab antigen binding group, in fact
many more configurations and combinations have been studied and engineered
for use in biopharmaceuticals, biosensors and diagnostics.
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Figure 6.1 IgG Antibody Structure. (Source: Invitrogen)
Fragmentation of antibodies is done using proteolysis reactions
(degradation of protein by enzymes) using enzymes such as papain, or pepsin or
ficin, and then subsequent purification steps are taken to separate Fc segments
and non-fragmented whole antibodies from the desired Fab or F(ab’)2 fragments.
6.2. Materials and Methods
6.2.1. Materials and Chemicals
Included in this list are the materials, chemicals, and equipment new to
this phase of the project that were not included in the previous sections.
Polycarbonate filters and polystyrene latex particle standards where obtained
from Sigma Chemical. The antibody fragmentation kit (Immunopure ® IgG1 Fab
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and F(ab’)2 44880) was purchased from Pierce Biotechnology. Propidium iodide
nuclear stain (H-1300) was obtained from Vector Labs. The gold particles were a
gift from Ed Haller, USF Health Pathology. Embed media and components for
TEM (and assistance) were provided, kindly, by Dr Karl Muffly.
Table 6.1 Equipment for Uptake Studies.
Equipment
Lipid Extruder and

Manufacturer

Model

Northern Lipids

Thermobarrel 10 ml

Fisher

Isotemp Open-Bath

Assembly
Water bath

Circulator
Submicron Dynamic Light

Malvern

Nano-S

Leica

SP3

Scattering Instrument
Confocal Microscope

6.2.2. Methods
6.2.2.1.

Extrusion of Niosomes

Prior to extrusion the niosomes were prepared through the hydration step
and then frozen overnight. Freezing and thawing the vesicle preparations
prompts hydration of the lipids and equal distribution of encapsulated materials.
The niosomes were extruded using a bench top stainless steel 10 ml
Thermobarrel LipexTM Extruder. Figure 6.2 shows the extruder and indicates the
functional parts. In order to set up the extrusion process the extruder must be
disassembled so that the filter package can be put in place. Two polycarbonate
filters were stacked on top of a mesh disk and a support disk within the cavity of
the filter support base and secured under an o-ring. A drop or two of de-ionized
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(DI) water was added between each filter while stacking to ensure good seating.
The correct alignment of the filters is crucial to the extrusion process; poor
alignment increases extrusion time and may necessitate changing filters before
the extrusion sequence is complete. The barrel of the extruder was replaced and
secured with wing nuts.

Figure 6.2 Extruder Assembly. (Source: Northern Lipids Extruder Handbook)

The vesicle suspension was pushed through the polycarbonate filters
using high pressure nitrogen gas (N2) supplied through high pressure lines. The
direct pressure into the system from the N2 tank was controlled through a valve
on the delivery tubing which is coupled to the gas inlet.
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Figure 6.3 Nitrogen Delivery to Extruder. (Adapted from Northern Lipids Extruder
Handbook.)
The water jacket of the extruder was supplied 60˚C DI water by a heated
water bath which was circulated by a peristaltic pump. Once the circulating water
equilibrated the extruder temperature, the filter assembly was conditioned by
expressing 8-10 ml of heated PBS through it. The pressure of the PBS delivery
was relatively low; setting the pressure to 200 psig, and rapidly opening and
closing the valve was sufficient to expel the liquid.
Once the filters are conditioned, the heated niosome suspension was
pipetted into the sample inlet. Control of the niosome suspension temperature is
important because extrusion must be done above the gel-to-liquid crystalline
phase transition temperature of the surfactant component (or in the case of
phospholipids, the component with the saturated alkyl tail) as described in
Section 4.2.1.1.

The temperature of the sample added to the inlet was allowed

to equilibrate for a moment before starting the extrusion (this is repeated at each
successive step). The valve was opened to allow the pressure to push the
niosome suspension through the filters. The extruded sample was expressed
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from the outlet tube once the extrusion process was underway. If sample was
not expressed within a few seconds, the pressure was increased until the
solution began to flow from the tube. The maximum pressure set by the
manufacturer was 800 psig. Once the extruded sample was captured, the
system pressure was vented by opening the pressure relief valve, and the
sample was returned to the inlet. This process was repeated ten times and loss
from the process was usually less than 10%. After extrusion, the niosome
sample was ready for the GEC process.
6.2.2.2.

Dynamic Light Scattering Measurements

Dynamic light scattering was used to measure the size of the extruded
and purified vesicle suspensions using a Malvern Instruments Nanosizer S.
Since the PSS particle analyzer (Section 4.2) had a lower detection limit of 0.5

µm diameter particles, the new instrument was required to monitor the size and
stability of the extruded vesicles. The Malvern system provides size, molecular
weight, and dispersity data using dynamic light scattering measurements with
autocorrelation function. The data results in a poly dispersity index which is a
measure of the width of the particle size distribution peak of the sample. The
instrument allowed measurements of post GEC particles suspended in PBS.
Operating parameters were programmed for measuring samples specifically in a
standard operating procedure (SOP) in the instrument software (DTS). The
material properties, refractive index and UV absorbance of the material to be
measured and the dispersant are input. Refractive index was measured on a
refractometer, and the UV absorbance of the niosome suspension at red laser
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wavelength (633 nm) was measured using a UV spectrophotometer. These
values are used to allow the conversion of the intensity distribution to a volume or
number distribution.
Outputs from individual measurements include intensity and volume
particle size distributions, cumulants and distribution fit curves, intensity and
volume statistics, and the correlation data. Calibration of the system was done
with polystyrene latex standards. Figure 6.4 shows the intensity PSD of a 60 nm
and 220 nm mixture of polystyrene latex particle standards, and the Figure 6.5
shows the correlation function curve. The PSS system (as described in Section
4.2.2.2) provided actual counts of particles, due to the single particle sensing
measurement algorithm, whereas the Malvern instrument provides a distribution
relative to a measured population-the area under the curve of the size distribution
of the Nanosizer data is always 100%, and the area under the curve of the PSS
size distribution is the number of particles measured and counted by the
instrument. Due to the difference in the underlying physics of these particle
characterization tools, their data did not align well. Despite claims to the contrary
by the manufacturer, dispersions of vesicles between 700-1000 nm did not
measure accurately or repeatedly in the Malvern instrument, at any dilution. This
would probably be due to the size limitation of Brownian motion.
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Figure 6.4 Particle Size Distribution of 60 nm and 220 nm Standards.

Figure 6.5 Correlation Function Curve of the Standards.
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6.2.2.3.

Antibody Fragmentation

Antibodies were fragmented using a commercially available kit from Pierce
according to the manufacturer’s instructions. While the components of the
columns and buffers are proprietary, essentially the process is the pH dependent
digestion of the hinge proteins of the antibody by the thiol protease enzyme ficin
(MW 25 kDa) in the presence of the amino acid cysteine. At a concentration of 1
mM cysteine, ficin will produce F(ab’)2 fragments, and at a concentration of 10
mM cysteine, ficin will produce Fab fragments. The digestion reaction takes
place in a column and the resulting fragments are eluted out in different fractions
using different buffers. The UV absorption of the fractions was measured and a
balance of proteins found that the initial yield was 70%. The protein
concentrations were measured using extinction coefficients of εFab= 7.5 x 104,
and εIgG= 22.1 x 104 using Beers Law (see Section 4.2).
6.2.2.4.

Endothelial Cell Culture and Fixation Techniques

Cells were cultured and activated as previously described in section 5.2.
For confocal studies the cells were grown on 8 well micro-slides, for TEM the
cells were grown on cover slips to allow for embedding into the resin. Prior to
incubation with live cells, the INs were filtered for sterility using a 0.2 µm syringe
filter to eliminate possible contaminants.
For the TEM studies a dilute solution of 15 nm spherical gold particles was
encapsulated in 10% Tw-CC niosomes which were extruded, purified with GEC,
and conjugated to IM7 antibodies in the usual manner. The gold particles were
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used in the niosomes to provide a strong signal during the TEM imaging. Prior to
IN incubation, the cells were well rinsed with warmed PBS.
6.2.2.5.

Fixation Techniques for Confocal Microscopy

Fluorescent IN suspensions were diluted 1:1 in serum free endothelial media
(to avoid unwanted protein interactions) and incubated with live bovine aortic
endothelial cells (BAECs) at 37˚C for varied times. After incubation the vesiclemedia mixture was discarded and the cells were rinsed three times with room
temperature PBS and then were fixed with 1% paraformaldehyde in PBS for 15
minutes. After fixation, the cells were PBS rinsed again and incubated with 0.1%
Triton X 100 solution for three minutes, to encourage membrane permeability for
the nuclear stain, propidium iodide, which was left to penetrate for 30 minutes.
Once the staining was complete, the cells were rinsed again, and the wells were
removed. A few drops of hard setting mounting solution were added to each
slide and a glass coverslip was placed over the cells and allowed to harden
overnight.
6.2.2.6.

Fixation Techniques for Transmission Electron Microscopy

Incubation of cells with INs with the gold containing INs was done as
described for the confocal studies. Once the incubation was complete the cells
were rinsed three times with room temperature PBS. Cells were fixed with a
2.5% solution of glutaraldehyde for 15 minutes at room temperature. Fixation of
cells for TEM was similar to that of the SEM procedure. A 1.5% potassium
ferricyanide/1% osmium tetroxide solution in DI water was added to the rinsed
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cells and left to fix for an hour in the dark. The cells were rinsed three times for
10 minutes each in 0.1M sodium acetate buffer. The lipid membranes were
stabilized by fixing in a 1.5% solution of uranyl acetate in a 0.1 Tris buffer, pH 6.3
for 30 minutes and then were rinsed three times with DI water.
Once the final fixation step was complete the cells went through a series
of dehydration steps. A series of ethanol in water was added as follows for 5
minutes each, 30%, 70%, 95%, and 100% ethanol for 15 minutes. After the
alcohol series, the cells were cleared with 100% propylene oxide for 15 minute,
and then a mixture of 100% propylene oxide mixed 1:1 with the embedding
media. The embedding media was mixed together per the instructions from the
EMS Technical Data Sheet for Araldite 502/EMBED-812 Embedding media as
follows: Embed-812 -13.75 g, Araldite 502 -8.5 g, DDSA -27.5 g, DMP-30-0.9 g.
The cells were embedded in the 1:1 mixture and allowed to dry overnight, and
then was capsulated in pure embedding media. The embedded cells were
sectioned with a diamond knife and fixed onto copper grids stained with 8%
uranyl acetate and lead citrate.
6.2.3. Confocal Microscopy
The confocal images were captured with a Leica SP2 using 40x oil
objectives with FITC and rhodamine filters. The argon laser (blue light for green
labels) provided wavelengths 458-514 nm, and the helium neon laser (red light
for far red labels) provided light at a wavelength of 633 nm. The Leica confocal
software (LCS) was used for imaging and for post-image capture processing.
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Once the fluorescently stained cell nuclei images were visually confirmed
and focused by viewing through the microscope eyepiece, the image capture
software was set up. The two photomultiplier (PMT) gains and offsets were set
for clarity and reduction of background noise, where possible. Figure 6.6 shows
the image acquisition screen where the settings are adjusted in the software.
Table 6.2 shows the PMT gain and offset and z position settings for the
samples examined.

Figure 6.6 Leica Confocal Software Image Acquisition Window.
Table 6.2 Confocal Settings.
Sample
Control
20min-dim
20min-brt
1hour-run1
1hour-run2

PMT 1
PMT 2
Z/Y Position
Gain
Offset
Gain Offset
(microns)
632
-11%
616
-7%
-42
520
-15%
464
-4%
-49
549
-14%
568
-14%
-28
862.3
-5.10%
847
-3.60%
-29
862.3
-5.10%
847
-3.60%
-29

113

Once the settings are established the image capture stack has to be defined
prior to going into scan mode. Figure 6.7 shows the schematic for setting the z/y
position in the LCS software. By scrolling through the image using the z position
the bottom and top positions were set to mark the start and end of the captured
stack.

Figure 6.7 Spatial Setting for Scan Mode Imaging.

6.3. Experimental Designs
Extrusion experiments were evaluated by taking aliquots of sample at each
extrusion pass. These samples were examined for size and entrapment of dye
by GEC elution and DLS. The GEC elution profiles were created by fluorescent
measurements of sequentially eluted fractions. Particle size distribution was
measured by DLS to see the effect of extrusion passes on vesicle formation and
dispersity.
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For the confocal uptake studies with whole antibodies conjugated to
fluorescent immuniosomes incubation times examined were 20 mins, 1 hour, 2
hours, and a control of 2 hours at 4˚C to check for non specific binding. Confocal
images of INs conjugated to IM7 Fab fragments were measured at 1 hour. TEM
incubation time was 1 hour. All antibody or fragment coating was at a done at
concentrations of 5 µg/ml.
6.4. Results
6.4.1. Extrusion Results
In Figure 6.8 the fluorescence chromatograms show the GEC elution of each
sample. The first peak represents the fluorescent signal from the niosomes
(partially quenched due to concentration) and the second peak represents the
unencapsulated free dye. Figure 6.9 shows the particle size distribution of the
niosome fractions captured during GEC.

115

Figure 6.8 Elution of Extrusions 0-10 for a 10% TW-CC-CF Hydration Sample.

Figure 6.9 Dynamic Light Scattering Data of Extruded Samples.
The cell nuclei are stained red in the confocal images, and the INs are green.
All images shown are at the maximum area of cell nuclei. Figure 6.10 shows the
20 min incubation. The z value represents the depth within the stack that the
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image represents. Figure 6.11 shows the 1 hour incubation, and Figure 6.12 is
the 2 hour incubation. The control cells are shown in Figure 6.13. These figures
represent incubations with whole antibody bound INs. The LCS software
provided a post imaging function called slice that allowed for a cross section of xz or y-z plane to be viewed. The narrow images shown in Figure 6.14 are
individual cross sections for each incubation slide already shown. The final
confocal image is seen in Figure 6.15 representing the incubation of BAECs with
fragment conjugated immunoniosomes.

Figure 6.10 Confocal BAECs 20 Minute Incubation. Image at -7.001 mm (Range
of stack: 0,-12.537 mm)
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Figure 6.11 Confocal BAECs I Hour Incubation. Image at -11.56 mm (Range of
stack: 0,-20.00 mm)

Figure 6.12 Confocal BAECs 2 Hour Incubation. Image at -11.07 mm (Range of
stack: 0, 20.03 mm)
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Figure 6.13 Confocal BAECs Control. Incubation at 4° C for 2 hrs. Image at
4.88 mm (Range of stack: 11.07,0 mm)

Figure 6.14 Confocal Cross Sections.
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Figure 6.15 Fab-IN BAEC Confocal Image.
6.4.2. TEM
Figure 6.16 shows the TEM image a single endothelial cell captured from the
incubation of INs containing gold particles with BAECs. The arrows indicate the
niosomes bound to the surface of the endothelial cell.

Figure 6.16 TEM of Au-INs.
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6.5. Conclusions

The extrusion studies indicated that eight passes through the system is
preferable for these vesicles versus the suggested ten passes used in the
synthesis of liposomes. Each successive extrusion pass up until the eight
showed an increase in the formed niosome signal of Figure 6.8, and
correspondingly showed a taller and sharper peak in the dynamic light scattering
data of Figure 6.9. In each data set, reduction of niosome formation and peak
was seen in the tenth pass sample.
The confocal images suggest uptake of immunoniosomes by live endothelial
cells. Penetration of IM7-niosomes continues between 20 min and 1 hour, but
does not appear to increase appreciatively thereafter. The cross section images
raise the possibility that INs are attaching to the junctions between the cells,
although there are niosomes visible in some images near nuclei. Controls show
no binding at 4˚C. Absolute verification of location of the vesicles either within or
on the surface of the cell remains to be done. Membrane staining was attempted
to clarify the imaging, but since the nature of the vesicle membrane is analogous
to that of a cell membrane, cross staining did not allow for the desired distinction
of IN position using that technique. An independent measure is needed to
confirm uptake such as radio labeling of vesicle components or encapsulated
material.
The IN-Fab incubation showed very sparse binding. This may be due to
disruption of the antigen couple of the fragment dissociating when exposed to the
binding pH. Using the F(ab’)2 fragments instead of the single Fab’s may provide

121

binding closer to that of the whole antibodies and should better preserve the
antigen binding sites. As it stands although the potential for fragment use is
demonstrated, the fragment binding requires optimization.
The TEM image shows adhesion to the surface of cell by the gold INs, none
were observed within the cell, however a very small sample of cells were
identified in the media, and an improvement of the cell embedding technique may
allow for clearer data.
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7. Conclusions and Contributions
7.1. Introduction
The research that this document represents created a new drug delivery
system with a novel linking chemistry targeted to treat a very significant
pathological condition, atherosclerosis. The long term goal of this research was
to create, test, and optimize a drug delivery carrier with a targeting vector that
could be used to treat the vulnerable plaque of atherosclerosis and test it
experimentally in vivo in an atherosclerotic animal model.
The fixed cell binding results of this research strongly demonstrate and ability
of the immunoniosome to bind to a target antigen and to do so selectively and
specifically. The uptake results do not definitively demonstrate the exact fate of
the IM7 conjugated niosomes when bound to inflammatory endothelial cells.
There has been sufficient demonstration within the body of liposome literature to
establish that the correct antigen-antibody couple will enable the uptake of
antibody bearing vesicles into the endothelium through endocytosis. Further
studies evaluating uptake of immunoniosomes by endothelial cells will need to be
pursued.
Regardless of uptake, the binding of niosomes bearing drug payload has the
potential for therapeutic effect by virtue of localization and antigen binding site
blocking. If a drug bearing particle is localized to a pathological site, in situ drug
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release will provide higher concentration of drug at the desired location than a
systemic delivery would. Also, a critical factor in the progression of inflammatory
diseases, and the build up of atherosclerotic plaque, is the destructive
proliferation of inflammatory cells at the sites of chronic inflammation. By
blocking the binding of inflammatory cells and the cell uptake sites, their
accumulation within the tissues would be mitigated. Whether the targeted
vesicles are taken up by the cells through endocytosis, or remain on the surface
of the inflammatory site, the potential for treatment remains.
The immunoniosome system was evaluated in this research for use in
targeting inflammatory processes; it would not necessarily be limited to that
application. The system is capable of encapsulating a solution of either
hydrophilic or hydrophobic drug, and of binding to any IgG and, except where
limited by size or surface hindrances, any protein. With these capacities, many
different applications of the system are possible and remain to be pursued. The
creation of the Tween 61-cyanuric chloride linker provides a highly reactive
binding moiety which can undergo nucleophilic substitution reactions easily and
without prior derivatization of the binding species. The potential of the system to
be used for other applications is significant.
7.2. Contributions
The contributions of this research to the field of targeted drug delivery include
the synthesis and characterization of a novel formulation of an antibody targeted
non ionic surfactant vesicle drug carrier. There is no information in the literature
describing niosomes composed of a blend of surfactants as a tool to
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simultaneously maintain required physical properties while creating linking
moieties. The creation of an antibody linker by the functionalization of a
polyoxyethylene sorbitan monostearate molecule is novel, as is the creation of
the polyoxyethylene sorbitan monostearate-cyanuric chloride linker molecule.
There is no reported use of non ionic surfactant vesicles designed for active
targeting with monoclonal antibodies.
7.3. Future Work
Future work in the vesicle characterization of this research includes the
further investigation of uptake of INs by activated endothelial cells, and a
refinement of the antibody fragment binding process. Entrapment of an HMG
CoA reductase inhibitor drug, atorvastatin, will be pursued prior to the onset of
the in vivo animal study. The protocol for the study has already been developed
and granted approval by the USF IACUC and the US Army Medical Research
and Material Command Animal Care and use Review Office. Table 7.1 outlines
the experimental design of the research.
The atherosclerotic animal model that will be used in the experiments is a
knock out mouse which lacks the ligand apolipoprotein E (apoE) which promotes
lipoprotein clearance. The apoE- deficient mice are bred using homologous
recombination in embryonic stem cells to be susceptible to developing
atherosclerosis.
The animals will be fed a high fat diet to encourage the formation and
progression of atherosclerotic lesions and plaque. After the 8-10 week feeding
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period, the treatment phase lasts 6 weeks. Treatments of experimental groups
are outlined in Table 7.1.
Table 7.1 Future Work: In Vivo Atherosclerotic Mouse Study
Treatment Group
(n=6 for all)
Test low

Test high

Control targeted non drug
Control non targeted with
drug
Control free drug low
Control free drug high
Control injection

Treatment
1. Surfactant vesicle coated with
antibody fragments and containing
drug atorvastatin (test substance-low
drug concentration)
2. Surfactant vesicle coated with
antibody fragments and containing
atorvastatin (test substance-high drug
concentration)
3. Surfactant vesicle coated with
antibody fragments and containing
buffered saline solution
4. Surfactant vesicle without antibody
containing atorvastatin
5. Free drug atorvastatin low
concentration (control)
6. Free drug atorvastatin high
concentration (control)
7. Buffered saline (control)

Treatments will be administered by tail vein injection, and weekly blood
samples will be taken by submandibular bleeding to assess blood cholesterol,
triglycerides, and atherosclerotic markers (e.g. C-reactive protein). Weekly body
weight will also be measured.
At the end of the treatment period, the mouse aortas will be evaluated for
differences in plaque progression, the bio-distribution of the atorvastatin drug in
the animal’s organs will be assessed, and the lipid blood levels will be studied.
The expectation from this study is that the targeted drug treatment group will
show a reduction of plaque progression relative to the free drug groups and
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controls. Additionally the study may demonstrate the extrahepatic effects of the
statin on the build up of plaques, since statin treatment does not affect the
production of cholesterol in the liver in the mouse model.
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Appendix A. Particle Sizing Systems Data and Software Output
The images below are Particle Sizing Systems Accusizer software output
from a 3 size polystyrene latex standard for size and count calibration of
instrument. The axes scales can be set, and the y axis can display units of
number of particles counted (# Part.) or numbers of particles counted per ml of
sample injected for analysis (# Part./ml as shown). For a given injection volume
the cumulative number of counts can be found in the volume fraction calculation
menu in the display menu. To obtain the number of particles per ml divide the
calculated number of particles listed in the volume fraction calculation by sample
volume injected. For example in the sample below 0.025 ml was injected. The
calculated # is 147011. The total number per ml is 5.88 x 106 particles per ml.

Figure A.1 Particle Size Distribution of Standards
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Figure A.2 Sample Number Calculation
:
Table A.1 Data Exported From PSD ASCII File
Particle Sizing Systems, Inc.
Santa Barbara, Calif.,
USA
Model 780 AccuSizer
Caption: standard MML 0.7, 1. 5 um peaks 25 uL
injection
File Name =
3_24_03.003
Sensor Model:
LE400-0.5
S/N:
8910 Cal.
File:
SUM
Elapsed Time of Data
60 Sec.
Collection =
Background File =
NONE
Total # Part. Sized
101593
(>=Thres. 0.52 um ) =
Calculated Total No. of
150625
Particles in Sample =
Dilution Factor =
1.48
Fluid Volume Sampled
60 ml
No. of
512
=
Channel
s=
NUM-WT Mean =
0.91 um
Mode =
0.73 um
VOL-WT Mean =

7.93 um

Mode =

5.34 um

0008910s.sns

Median
=
Median
=

Summary of Detailed Distribution, Weightings
Diameter

# Part.

(microns)

Sized
0.52418
0.5313
0.53851

Cum Num % Vol % Cum
Vol Num %
Num
Num %
>=Diam.
>=Diam. >=Diam.
288 10159
0.283 0.007
100
100
3
328 10130
0.323 0.009
99.717
99.993
5
312 10097
0.307 0.009
99.394
99.984
7
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0.73
5.32
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0.55324
0.56076
0.56837
0.57609
0.58392
0.59185
0.59989
0.60804
0.6163
0.62467
0.63315
0.64175
0.65047
0.65931
0.66826
0.67734
0.68654
0.69586
0.70532
0.7149
0.72461
0.73445
0.74443
0.75454
0.76479
0.77517
0.7857
0.79638
0.80719
0.81816
0.82927
0.84054
0.85195
0.86352
0.87525
0.88714
0.89919
0.91141
0.92379
0.93633
0.94905
0.96194
0.97501
0.98825
1.00168
1.01528
1.02907
1.04305
1.05722
1.07158
1.08614
1.10089
1.11584

400 10031
3
368 99913
389 99545
818 99156
799 98338
715 97539
643 96824
631 96181
265 95550
571 95285
285 94714
701 94429
1084 93728
709 92644
1647 91935
2336 90288
1655 87952
5436 86297
7096 80861
3987 73765
8772 69778
9730 61006
8951 51276
3857 42325
6126 38468
4295 32342
2792 28047
1624 25255
509 23631
680 23122
447 22442
331 21995
250 21664
202 21414
181 21212
225 21031
180 20806
181 20626
354 20445
267 20091
197 19824
190 19627
196 19437
313 19241
254 18928
794 18674
784 17880
1684 17096
2565 15412
2938 12847
2610 9909
1310 7299
1259 5989

0.394

0.012

98.74

99.965

0.362
0.383
0.805
0.786
0.704
0.633
0.621
0.261
0.562
0.281
0.69
1.067
0.698
1.621
2.299
1.629
5.351
6.985
3.924
8.634
9.577
8.811
3.797
6.03
4.228
2.748
1.599
0.501
0.669
0.44
0.326
0.246
0.199
0.178
0.221
0.177
0.178
0.348
0.263
0.194
0.187
0.193
0.308
0.25
0.782
0.772
1.658
2.525
2.892
2.569
1.289
1.239

0.012
0.013
0.028
0.028
0.026
0.025
0.025
0.011
0.025
0.013
0.033
0.053
0.036
0.088
0.13
0.096
0.327
0.445
0.26
0.596
0.688
0.659
0.296
0.489
0.357
0.242
0.146
0.048
0.066
0.046
0.035
0.028
0.023
0.022
0.028
0.023
0.024
0.05
0.039
0.03
0.03
0.032
0.054
0.046
0.148
0.153
0.341
0.541
0.646
0.597
0.312
0.312

98.346
97.984
97.601
96.796
96.01
95.306
94.673
94.052
93.791
93.229
92.948
92.258
91.191
90.493
88.872
86.573
84.944
79.593
72.608
68.684
60.049
50.472
41.661
37.865
31.835
27.607
24.859
23.26
22.759
22.09
21.65
21.324
21.078
20.879
20.701
20.48
20.303
20.124
19.776
19.513
19.319
19.132
18.939
18.631
18.381
17.6
16.828
15.17
12.646
9.754
7.185
5.895

99.953
99.941
99.928
99.901
99.872
99.846
99.821
99.796
99.784
99.76
99.747
99.714
99.66
99.624
99.536
99.407
99.311
98.984
98.539
98.279
97.683
96.995
96.336
96.04
95.55
95.193
94.951
94.805
94.757
94.691
94.645
94.61
94.582
94.559
94.538
94.51
94.486
94.462
94.412
94.373
94.343
94.312
94.28
94.226
94.18
94.032
93.88
93.538
92.997
92.352
91.754
91.442
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1.131
1.14636
1.16193
1.17772
1.19371
1.20993
1.22636
1.24302
1.2599
1.27702
1.29436
1.31194
1.32976
1.34783
1.36613
1.38469
1.4035
1.42256
1.44189
1.46147
1.48132
1.50144
1.52184
1.54251
1.56346
1.5847
1.60622
1.62804
1.65015
1.67257
1.69529
1.71832
1.74166
1.76531
1.78929
1.81359
1.83823
1.8632
1.88851
1.91416
1.94016
1.96651
1.99322
2.0203
2.04774
2.07555
2.10375
2.13232
2.16129
2.19064
2.2204
2.25056
2.28113
2.31211

670
328
134
106
60
47
31
39
37
22
17
34
32
19
28
23
14
22
13
13
14
10
15
8
11
14
16
6
7
10
14
6
9
9
13
8
3
5
7
6
3
10
5
1
3
3
3
3
3
3
9
4
4
4

4730
4060
3732
3598
3492
3432
3385
3354
3315
3278
3256
3239
3205
3173
3154
3126
3103
3089
3067
3054
3041
3027
3017
3002
2994
2983
2969
2953
2947
2940
2930
2916
2910
2901
2892
2879
2871
2868
2863
2856
2850
2847
2837
2832
2831
2828
2825
2822
2819
2816
2813
2804
2800
2796

0.659
0.323
0.132
0.104
0.059
0.046
0.031
0.038
0.036
0.022
0.017
0.033
0.031
0.019
0.028
0.023
0.014
0.022
0.013
0.013
0.014
0.01
0.015
0.008
0.011
0.014
0.016
0.006
0.007
0.01
0.014
0.006
0.009
0.009
0.013
0.008
0.003
0.005
0.007
0.006
0.003
0.01
0.005
0.001
0.003
0.003
0.003
0.003
0.003
0.003
0.009
0.004
0.004
0.004
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0.173
0.088
0.038
0.031
0.018
0.015
0.01
0.013
0.013
0.008
0.007
0.014
0.013
0.008
0.013
0.011
0.007
0.011
0.007
0.007
0.008
0.006
0.009
0.005
0.008
0.01
0.012
0.005
0.006
0.008
0.012
0.005
0.008
0.009
0.013
0.009
0.003
0.006
0.008
0.008
0.004
0.014
0.007
0.001
0.005
0.005
0.005
0.005
0.005
0.006
0.018
0.008
0.008
0.009

4.656
3.996
3.673
3.542
3.437
3.378
3.332
3.301
3.263
3.227
3.205
3.188
3.155
3.123
3.105
3.077
3.054
3.041
3.019
3.006
2.993
2.98
2.97
2.955
2.947
2.936
2.922
2.907
2.901
2.894
2.884
2.87
2.864
2.855
2.847
2.834
2.826
2.823
2.818
2.811
2.805
2.802
2.793
2.788
2.787
2.784
2.781
2.778
2.775
2.772
2.769
2.76
2.756
2.752

91.13
90.957
90.869
90.831
90.8
90.782
90.767
90.757
90.744
90.73
90.722
90.716
90.702
90.688
90.68
90.667
90.656
90.65
90.638
90.631
90.624
90.616
90.61
90.6
90.595
90.588
90.578
90.566
90.561
90.556
90.547
90.535
90.53
90.521
90.512
90.499
90.491
90.487
90.481
90.473
90.465
90.462
90.448
90.441
90.439
90.435
90.43
90.425
90.42
90.414
90.409
90.391
90.383
90.375

Appendix A. (Continued)
2.34352
2.37535
2.40762
2.44032
2.47347
2.50706
2.54112
2.57563
2.61062
2.64608
2.68202
2.71845
2.75538
2.7928
2.83074
2.86919
2.90816
2.94766
2.9877
3.02828
3.06942
3.11111
3.15337
3.1962
3.23961
3.28362
3.32822
3.37343
3.41925
3.46569
3.51277
3.56048
3.60885
3.65787
3.70755
3.75791
3.80896
3.86069
3.91313
3.96629
4.02016
4.07477
4.13012
4.18622
4.24308
4.30071
4.35913
4.41834
4.47835
4.53918
4.60084
4.66333
4.72668
4.79088

3
4
1
3
4
3
2
2
3
3
0
3
2
2
0
4
1
3
3
5
1
3
0
2
1
1
0
3
0
0
0
0
1
2
0
1
1
3
0
2
5
3
2
2
1
4
2
6
1
6
6
4
8
26

2792
2789
2785
2784
2781
2777
2774
2772
2770
2767
2764
2764
2761
2759
2757
2757
2753
2752
2749
2746
2741
2740
2737
2737
2735
2734
2733
2733
2730
2730
2730
2730
2730
2729
2727
2727
2726
2725
2722
2722
2720
2715
2712
2710
2708
2707
2703
2701
2695
2694
2688
2682
2678
2670

0.003
0.004
0.001
0.003
0.004
0.003
0.002
0.002
0.003
0.003
0
0.003
0.002
0.002
0
0.004
0.001
0.003
0.003
0.005
0.001
0.003
0
0.002
0.001
0.001
0
0.003
0
0
0
0
0.001
0.002
0
0.001
0.001
0.003
0
0.002
0.005
0.003
0.002
0.002
0.001
0.004
0.002
0.006
0.001
0.006
0.006
0.004
0.008
0.026
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0.007
0.01
0.002
0.008
0.011
0.008
0.006
0.006
0.01
0.01
0
0.011
0.007
0.008
0
0.017
0.004
0.014
0.014
0.025
0.005
0.016
0
0.012
0.006
0.006
0
0.021
0
0
0
0
0.008
0.017
0
0.009
0.01
0.031
0
0.022
0.058
0.036
0.025
0.026
0.014
0.057
0.03
0.092
0.016
0.1
0.104
0.072
0.151
0.511

2.748
2.745
2.741
2.74
2.737
2.733
2.73
2.729
2.727
2.724
2.721
2.721
2.718
2.716
2.714
2.714
2.71
2.709
2.706
2.703
2.698
2.697
2.694
2.694
2.692
2.691
2.69
2.69
2.687
2.687
2.687
2.687
2.687
2.686
2.684
2.684
2.683
2.682
2.679
2.679
2.677
2.672
2.669
2.667
2.666
2.665
2.661
2.659
2.653
2.652
2.646
2.64
2.636
2.628

90.366
90.359
90.349
90.347
90.339
90.328
90.32
90.314
90.308
90.298
90.288
90.288
90.278
90.27
90.262
90.262
90.245
90.241
90.227
90.213
90.188
90.183
90.167
90.167
90.155
90.149
90.143
90.143
90.122
90.122
90.122
90.122
90.122
90.114
90.097
90.097
90.087
90.077
90.046
90.046
90.024
89.966
89.93
89.905
89.878
89.865
89.808
89.778
89.686
89.67
89.57
89.465
89.393
89.242
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4.85595
4.92191
4.98877
5.05653
5.12522
5.19483
5.26539
5.33691
5.40941
5.48288
5.55736
5.63284
5.70936
5.78691
5.86551
5.94518
6.02594
6.10779
6.19075
6.27484
6.36007
6.44646
6.53403
6.62278
6.71274
6.80392
6.89634
6.99001
7.08496
7.18119
7.27873
7.3776
7.47781
7.57939
7.68234
7.78669
7.89246
7.99966
8.10832
8.21846
8.33009
8.44324
8.55792
8.67417
8.79199
8.91141
9.03246
9.15515
9.2795
9.40555
9.5333
9.6628
9.79405

25
21
39
58
104
222
468
772
567
206
47
19
9
8
2
7
4
3
2
8
1
2
3
6
3
0
1
1
0
1
0
0
2
3
4
2
4
0
0
0
0
0
1
0
0
0
0
2
1
0
0
1
1

2644
2619
2598
2559
2501
2397
2175
1707
935
368
162
115
96
87
79
77
70
66
63
61
53
52
50
47
41
38
38
37
36
36
35
35
35
33
30
26
24
20
20
20
20
20
20
19
19
19
19
19
17
16
16
16
15

0.025 0.511
0.021 0.447
0.038 0.865
0.057 1.339
0.102
2.5
0.219 5.557
0.461 12.199
0.76 20.955
0.558 16.026
0.203 6.063
0.046
1.44
0.019 0.606
0.009 0.299
0.008 0.277
0.002 0.072
0.007 0.263
0.004 0.156
0.003 0.122
0.002 0.085
0.008 0.353
0.001 0.046
0.002 0.096
0.003 0.149
0.006 0.311
0.003 0.162
0
0
0.001 0.059
0.001 0.061
0
0
0.001 0.066
0
0
0
0
0.002 0.149
0.003 0.233
0.004 0.324
0.002 0.169
0.004 0.351
0
0
0
0
0
0
0
0
0
0
0.001 0.112
0
0
0
0
0
0
0
0
0.002 0.274
0.001 0.143
0
0
0
0
0.001 0.161
0.001 0.168
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2.603
2.578
2.557
2.519
2.462
2.359
2.141
1.68
0.92
0.362
0.159
0.113
0.094
0.086
0.078
0.076
0.069
0.065
0.062
0.06
0.052
0.051
0.049
0.046
0.04
0.037
0.037
0.036
0.035
0.035
0.034
0.034
0.034
0.032
0.03
0.026
0.024
0.02
0.02
0.02
0.02
0.02
0.02
0.019
0.019
0.019
0.019
0.019
0.017
0.016
0.016
0.016
0.015

88.732
88.22
87.773
86.909
85.57
83.07
77.512
65.313
44.359
28.333
22.27
20.83
20.223
19.924
19.647
19.575
19.313
19.156
19.034
18.95
18.597
18.551
18.455
18.306
17.994
17.832
17.832
17.774
17.713
17.713
17.647
17.647
17.647
17.497
17.264
16.94
16.772
16.42
16.42
16.42
16.42
16.42
16.42
16.309
16.309
16.309
16.309
16.309
16.034
15.892
15.892
15.892
15.731
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9.92708
10.06192
10.19859
10.33712
10.47753
10.61985
10.7641
10.91031
11.05851
11.20872
11.36097
11.51528
11.6717
11.83024
11.99093
12.1538
12.31889
12.48622
12.65582
12.82773
13.00197
13.17857
13.35758
13.53902
13.72292
13.90932
14.09825
14.28975
14.48385
14.68059
14.87999
15.08211
15.28697
15.49462
15.70508
15.91841
16.13463
16.35379
16.57593
16.80108
17.02929
17.2606
17.49505
17.73269
17.97356
18.21769
18.46515
18.71596
18.97018
19.22786
19.48903
19.75375
20.02207
20.29403

0
0
0
0
1
0
0
1
0
0
1
0
0
0
0
0
1
0
0
0
0
1
1
0
0
0
0
1
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
1
0
1
0
1
0
0
1
0
0

14
14
14
14
14
13
13
13
12
12
12
11
11
11
11
11
11
10
10
10
10
10
9
8
8
8
8
8
7
7
7
7
7
7
7
7
6
5
5
5
5
5
5
5
5
4
4
3
3
2
2
2
1
1

0
0
0
0
0.001
0
0
0.001
0
0
0.001
0
0
0
0
0
0.001
0
0
0
0
0.001
0.001
0
0
0
0
0.001
0
0
0
0
0
0
0
0.001
0.001
0
0
0
0
0
0
0
0.001
0
0.001
0
0.001
0
0
0.001
0
0
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0
0
0
0
0.205
0
0
0.232
0
0
0.262
0
0
0
0
0
0.334
0
0
0
0
0.409
0.426
0
0
0
0
0.521
0
0
0
0
0
0
0
0.72
0.75
0
0
0
0
0
0
0
1.037
0
1.124
0
1.219
0
0
1.376
0
0

0.014
0.014
0.014
0.014
0.014
0.013
0.013
0.013
0.012
0.012
0.012
0.011
0.011
0.011
0.011
0.011
0.011
0.01
0.01
0.01
0.01
0.01
0.009
0.008
0.008
0.008
0.008
0.008
0.007
0.007
0.007
0.007
0.007
0.007
0.007
0.007
0.006
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.004
0.004
0.003
0.003
0.002
0.002
0.002
0.001
0.001

15.563
15.563
15.563
15.563
15.563
15.358
15.358
15.358
15.126
15.126
15.126
14.864
14.864
14.864
14.864
14.864
14.864
14.53
14.53
14.53
14.53
14.53
14.121
13.696
13.696
13.696
13.696
13.696
13.175
13.175
13.175
13.175
13.175
13.175
13.175
13.175
12.454
11.704
11.704
11.704
11.704
11.704
11.704
11.704
11.704
10.668
10.668
9.543
9.543
8.324
8.324
8.324
6.948
6.948
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20.56969
20.84909
21.13229
21.41933
21.71027
22.00517
22.30407
22.60702
22.9141
23.22534
23.54082
23.86058
24.18468
24.51318
24.84615
25.18363
25.52571
25.87242
26.22385
26.58006
26.9411
27.30704
27.67796
28.05391
28.43497
28.82121
29.21269
29.60949
30.01168
30.41933
30.83252
31.25132
31.67581
32.10607
32.54217
32.9842
33.43222
33.88634
34.34662
34.81316
35.28603
35.76532
36.25113
36.74353

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.001
0
0
0
0
0
0

154

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6.948
0
0
0
0
0
0

0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0
0
0
0
0
0

6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
6.948
0
0
0
0
0
0

Appendix B. Akta Prime Chromatography Data Output
Generated reports for each sample run show user designated data,
method, run and evaluation notes.

Figure B.1 Akta Prime Elution Chromatogram Showing UV Absorbance and
Conductivity
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Appendix B. (Continued)

Figure B.2 Akta Prime Method Notes
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Appendix B. (Continued)
Each programmed method run created an overlay of all experimental
curves generated. The data for each curve represented in the overlay can be
individually exported as an ASCII file.

Figure B.3 Akta Prime Chromatogram Showing All Measures
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Appendix C. Fluorescent Plate Reader
The BioTek Instruments fluorescent plate reader uses KC Junior software
for creating an operating procedure and translating the intensity data into
concentration data based on a designated calibration curve.
Below are the steps for setting up a 96 well plate and the resulting data
available for export to Microsoft Excel.
C.1 Defined Protocol

Figure C.1 Fluorescent Plate Reader: Protocol Definition
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Appendix C. (Continued)

Figure C.2 Fluorescent Plate Reader: Defined Plate Reader Geometry
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Appendix C. (Continued)

Figure C.3 Fluorescent Plate Reader: Define Individual Well Measurement Types
C.2 Stored Standard Curve Example

Figure C.4 Fluorescent Plate Reader: Stored Standard Curve
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Appendix C. (Continued)
Measured Intensity

Figure C.5 Fluorescent Plate Reader: Fluorescence Intensity by Wells
C.3 Data Exported to Excel

Figure C.6 Fluorescent Plate Reader: Intensity Data Exported to Microsoft Excel
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Appendix D. Matlab™ Image Analysis
The Matlab program which produced this example output was constructed
by John Elliott, M.S. ChE while working in the Chemical Engineering Department
at USF in 2006-2007. The overall process of the image analysis and the images
produced was described in Section 5.2.4.3. Below is the data output from the
Matlab Command Window.
These examples were run with 20x magnification images files from BAECs
incubated with INs for 2 hours at 37˚C.

Command Window Output
caldata =
6x1 struct array with fields:
Area
Centroid
BoundingBox
X_Cal =
0.4669
handles =
figure1: 153.0455
pushbutton7: 7.0457
pushbutton6: 6.0457
listbox1: 5.0457
pushbutton5: 4.0457
pushbutton4: 3.0457
pushbutton3: 2.0457
pushbutton2: 1.0457
pushbutton1: 0.0457
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Appendix D. (Continued)
togglebutton1: 159.0455
axes3: 154.0455
output: 153.0455
filename: 'W1_20x_D1.tif'
root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\'
banner: [1024x1360x3 uint8]
Cal: 0.2180
h=
1
h=
2
celldata =
76x1 struct array with fields:
Area
Centroid
BoundingBox
max_area =
1243
cell_mean =
104.2558
max_area2 =
476
h=
3
filename2 =
W1_20x_F1a.tif
root_file2 =
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Appendix D. (Continued)
C:\Program Files\MATLAB71\work\images\10-05-06\
filename2 =
W1_20x_F1.tif
root_file2 =
C:\Program Files\MATLAB71\work\images\10-05-06\
h=
4
celldata22 =
1699x1 struct array with fields:
Area
Centroid
BoundingBox
handles =
figure1: 153.0455
pushbutton7: 7.0457
pushbutton6: 6.0457
listbox1: 5.0457
pushbutton5: 4.0457
pushbutton4: 3.0457
pushbutton3: 2.0457
pushbutton2: 1.0457
pushbutton1: 0.0457
togglebutton1: 159.0455
axes3: 154.0455
output: 153.0455
filename: 'W1_20x_D1.tif'
root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\'
banner: [1024x1360x3 uint8]
Cal: 0.2180
myX: [1 1360]
myY: [1 1024]
sub_A: [571x571x3 uint8]
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Appendix D. (Continued)
rect_userD: [10.0968 248.8353 570.2515 570.2515]
sub_B: [571x571 uint8]
sub_BB: [571x571 uint8]
sub_C: [571x571 logical]
labeled: [571x571 double]
numObjects: 76
RGB_label: [571x571x3 uint8]
numObjects2: 42
red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14]
ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2]
fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2]
A2: [1024x1360x3 uint8]
sub_A2: [571x571x3 uint8]
RGB_label2: [571x571x3 uint8]
nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
handles =
figure1: 153.0455
pushbutton7: 7.0457
pushbutton6: 6.0457
listbox1: 5.0457
pushbutton5: 4.0457
pushbutton4: 3.0457
pushbutton3: 2.0457
pushbutton2: 1.0457
pushbutton1: 0.0457
togglebutton1: 159.0455
axes3: 154.0455
output: 153.0455
filename: 'W1_20x_D1.tif'
root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\'
banner: [1024x1360x3 uint8]
Cal: 0.2180
myX: [1 1360]
myY: [1 1024]
sub_A: [571x571x3 uint8]
rect_userD: [10.0968 248.8353 570.2515 570.2515]
sub_B: [571x571 uint8]
sub_BB: [571x571 uint8]
sub_C: [571x571 logical]
labeled: [571x571 double]
numObjects: 76
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Appendix D. (Continued)
RGB_label: [571x571x3 uint8]
numObjects2: 42
red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14]
ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2]
fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2]
A2: [1024x1360x3 uint8]
sub_A2: [571x571x3 uint8]
RGB_label2: [571x571x3 uint8]
nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
finalpic: [571x571x3 uint8]
cellTotalCount: 80
handles =
figure1: 153.0455
pushbutton7: 7.0457
pushbutton6: 6.0457
listbox1: 5.0457
pushbutton5: 4.0457
pushbutton4: 3.0457
pushbutton3: 2.0457
pushbutton2: 1.0457
pushbutton1: 0.0457
togglebutton1: 159.0455
axes3: 154.0455
output: 153.0455
filename: 'W1_20x_D1.tif'
root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\'
banner: [1024x1360x3 uint8]
Cal: 0.2180
myX: [1 1360]
myY: [1 1024]
sub_A: [571x571x3 uint8]
rect_userD: [10.0968 248.8353 570.2515 570.2515]
sub_B: [571x571 uint8]
sub_BB: [571x571 uint8]
sub_C: [571x571 logical]
labeled: [571x571 double]
numObjects: 76
RGB_label: [571x571x3 uint8]
numObjects2: 42
red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14]
ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2]
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fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2]
A2: [1024x1360x3 uint8]
sub_A2: [571x571x3 uint8]
RGB_label2: [571x571x3 uint8]
nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
finalpic: [571x571x3 uint8]
cellTotalCount: 80
totalArea: 7.0877e+004
handles =
figure1: 153.0455
pushbutton7: 7.0457
pushbutton6: 6.0457
listbox1: 5.0457
pushbutton5: 4.0457
pushbutton4: 3.0457
pushbutton3: 2.0457
pushbutton2: 1.0457
pushbutton1: 0.0457
togglebutton1: 159.0455
axes3: 154.0455
output: 153.0455
filename: 'W1_20x_D1.tif'
root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\'
banner: [1024x1360x3 uint8]
Cal: 0.2180
myX: [1 1360]
myY: [1 1024]
sub_A: [571x571x3 uint8]
rect_userD: [10.0968 248.8353 570.2515 570.2515]
sub_B: [571x571 uint8]
sub_BB: [571x571 uint8]
sub_C: [571x571 logical]
labeled: [571x571 double]
numObjects: 76
RGB_label: [571x571x3 uint8]
numObjects2: 42
red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14]
ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2]
fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2]
A2: [1024x1360x3 uint8]
sub_A2: [571x571x3 uint8]
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RGB_label2: [571x571x3 uint8]
nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
finalpic: [571x571x3 uint8]
cellTotalCount: 80
totalArea: 7.0877e+004
cell_density: 0.0011
handles =
figure1: 153.0455
pushbutton7: 7.0457
pushbutton6: 6.0457
listbox1: 5.0457
pushbutton5: 4.0457
pushbutton4: 3.0457
pushbutton3: 2.0457
pushbutton2: 1.0457
pushbutton1: 0.0457
togglebutton1: 159.0455
axes3: 154.0455
output: 153.0455
filename: 'W1_20x_D1.tif'
root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\'
banner: [1024x1360x3 uint8]
Cal: 0.2180
myX: [1 1360]
myY: [1 1024]
sub_A: [571x571x3 uint8]
rect_userD: [10.0968 248.8353 570.2515 570.2515]
sub_B: [571x571 uint8]
sub_BB: [571x571 uint8]
sub_C: [571x571 logical]
labeled: [571x571 double]
numObjects: 76
RGB_label: [571x571x3 uint8]
numObjects2: 42
red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14]
ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2]
fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2]
A2: [1024x1360x3 uint8]
sub_A2: [571x571x3 uint8]
RGB_label2: [571x571x3 uint8]
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nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
finalpic: [571x571x3 uint8]
cellTotalCount: 80
totalArea: 7.0877e+004
cell_density: 0.0011
nioTotalCount: 1699
handles =
figure1: 153.0455
pushbutton7: 7.0457
pushbutton6: 6.0457
listbox1: 5.0457
pushbutton5: 4.0457
pushbutton4: 3.0457
pushbutton3: 2.0457
pushbutton2: 1.0457
pushbutton1: 0.0457
togglebutton1: 159.0455
axes3: 154.0455
output: 153.0455
filename: 'W1_20x_D1.tif'
root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\'
banner: [1024x1360x3 uint8]
Cal: 0.2180
myX: [1 1360]
myY: [1 1024]
sub_A: [571x571x3 uint8]
rect_userD: [10.0968 248.8353 570.2515 570.2515]
sub_B: [571x571 uint8]
sub_BB: [571x571 uint8]
sub_C: [571x571 logical]
labeled: [571x571 double]
numObjects: 76
RGB_label: [571x571x3 uint8]
numObjects2: 42
red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14]
ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2]
fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2]
A2: [1024x1360x3 uint8]
sub_A2: [571x571x3 uint8]
RGB_label2: [571x571x3 uint8]
nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
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nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1]
finalpic: [571x571x3 uint8]
cellTotalCount: 80
totalArea: 7.0877e+004
cell_density: 0.0011
nioTotalCount: 1699
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Appendix E. Confocal Image Processing Data
The following is a text file generated by the Leica Confocal Software which
details the operating parameters and the stacking instructions for combining the
fluorescent images.
Leica Microsystems Heidelberg GmbH
This file is intended for read-only purposes changes here will not affect the
images.
Date: Tuesday, June 19, 2007
Time: 16:05
File Version: 26000000
EXPERIMENT INFORMATION
Number of Images: 3
Type:
Series with 'tif'-files
DIMENSION DESCRIPTION #0
Pixel Size in Byte: 1
Resolution in Bit:
8
Max Value:
255.0000000000
Min Value:
0.000000e+000
Label:
I
Number of Dimensions:
4
Dimension_0:
120
Logical Size:
512
Physical Length:
1.365967e-004 m
Physical Origin:
0.000000e+000 m
Dimension_1:
121
Logical Size:
512
Physical Length:
1.365967e-004 m
Physical Origin:
0.000000e+000 m
Dimension_2:
6815843
Logical Size:
2
Physical Length:
0.000000e+000
Physical Origin:
0.000000e+000
Dimension_3:
122
Logical Size:
1
Physical Length:
0.000000e+000
Physical Origin:
0.000000e+000
Series Name:
Series038
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Description:
HARDWARE PARAMETER #0
AOTF (458)
49.328449
AOTF (476)
0.000000
AOTF (488)
50.671551
AOTF (514)
0.000000
AOTF (561)
50.012210
AOTF (633)
0.000000
AOTF (458)
0.000000
AOTF (476)
0.000000
AOTF (488)
0.000000
AOTF (514)
0.000000
AOTF (561)
0.000000
AOTF (633)
0.000000
PMT 1 Active Active
PMT 1 (Offs.)
-21.600000
PMT 1 (HV)
631.887456
PMT 2 Active Active
PMT 2 (Offs.)
-13.600000
PMT 2 (HV)
616.060961
PMT 3 Inactive
Inactive
PMT Trans Inactive
Inactive
Beam Expander
Beam Exp 6 Beam Exp 6
Excitation Beam Splitter FW
DD 488/568 DD 488/568
External Detection FW
Mirror Mirror
Hardware Type No.
2.000000
Scan Field Rotation
-0.038943
Rotation Direction
1
X Scan Actuator
Active Active
X Scan Actuator (Gain)
2.745308
X Scan Actuator (Offs.)
0.000000
Y Scan Actuator
Active Active
Y Scan Actuator (Gain)
2.745308
Y Scan Actuator (Offs.)
0.000000
Z Scan Actuator
Inactive
Inactive
Z Scan Actuator (POS)
-0.000048
Scan Speed
200.000000
Phase
10.546875
Y-Phase
0.122100
SP Mirror 1 (left)
500.000000
SP Mirror 1 (right)
550.000000
SP Mirror 1 (stain) FITC FITC
SP Mirror 2 (left)
570.000000
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SP Mirror 2 (right)
700.000000
SP Mirror 2 (stain) TRITC TRITC
SP Mirror 3 (left)
750.000000
SP Mirror 3 (right)
850.000000
SP Mirror 3 (stain) None None
Objective
HCX PL APO CS 40.0x1.25 OIL UV
40.0x1.25 OIL UV
Order number (Obj.)
506179
Numerical aperture (Obj.)
1.250000
SCANNER INFORMATION #0
RoiScan
0
IsSequential
0
ChaserUVShutter
0
ChaserVisibleShutter
0
MPShutter
0
UVShutter
0
VisibleShutter
1
ScanMode xyz
Active
Pinhole [m]
0.000081
Pinhole [airy]
0.998666
Size-Width [µm]
136.596680
Size-Height [µm]
136.596680
Size-Depth
0.000000
StepSize
[µm]
0.040703
Voxel-Width [µm]
0.266790
Voxel-Height [µm]
0.266790
Voxel-Depth
0.000000
Zoom
2.745308
Scan-Direction
1
Y-Scan-Direction
1
SequentialMode
0
Frame-Accumulation
1
Frame-Average
1
Line-Average
1
Resolution
8
Channels
2
Format-Width
512
Format-Height
512
Sections
1
TIME INFORMATION #0
Stamped Dimension:
2
Stamp_0:
2007:06:19,15:38:12:546
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Stamp_1:

2007:06:19,15:38:12:546

LUT DESCRIPTION #0
LUT_0
Name:
Green
Inverted (1=yes / 0=no): 0
LUT_1
Name:
Red
Inverted (1=yes / 0=no): 0
SEQUENTIAL INFORMATION #0
Sequence Count: 0
SERIES INFORMATION #0
Number of Series: 3
IMAGES INFORMATION #0
Number of Images: 2
Image Width:
512
Iamge Length:
512
Bits per Sample:
8
Samples per Pixel: 1
*************************************** NEXT IMAGE *********************************
DIMENSION DESCRIPTION #1
Pixel Size in Byte: 1
Resolution in Bit:
8
Max Value:
255.0000000000
Min Value:
0.000000e+000
Label:
I
Number of Dimensions:
4
Dimension_0:
120
Logical Size:
512
Physical Length:
1.365967e-004 m
Physical Origin:
0.000000e+000 m
Dimension_1:
121
Logical Size:
512
Physical Length:
1.365967e-004 m
Physical Origin:
0.000000e+000 m
Dimension_2:
6815843
Logical Size:
2
Physical Length:
0.000000e+000
Physical Origin:
0.000000e+000
Dimension_3:
122
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Logical Size:
Physical Length:
Physical Origin:
Series Name:
Description:

3
-3.256268e-007 m
-3.661267e-005 m
Series045

HARDWARE PARAMETER #1
AOTF (458)
49.328449
AOTF (476)
0.000000
AOTF (488)
50.671551
AOTF (514)
0.000000
AOTF (561)
50.012210
AOTF (633)
0.000000
AOTF (458)
0.000000
AOTF (476)
0.000000
AOTF (488)
0.000000
AOTF (514)
0.000000
AOTF (561)
0.000000
AOTF (633)
0.000000
PMT 1 Active Active
PMT 1 (Offs.)
-21.600000
PMT 1 (HV)
631.887456
PMT 2 Active Active
PMT 2 (Offs.)
-13.600000
PMT 2 (HV)
616.060961
PMT 3 Inactive
Inactive
PMT Trans Inactive
Inactive
Beam Expander
Beam Exp 6 Beam Exp 6
Excitation Beam Splitter FW
DD 488/568 DD 488/568
External Detection FW
Mirror Mirror
Hardware Type No.
2.000000
Scan Field Rotation
-0.038943
Rotation Direction
1
X Scan Actuator
Active Active
X Scan Actuator (Gain)
2.745308
X Scan Actuator (Offs.)
0.000000
Y Scan Actuator
Active Active
Y Scan Actuator (Gain)
2.745308
Y Scan Actuator (Offs.)
0.000000
Z Scan Actuator
Inactive
Inactive
Z Scan Actuator (POS)
-0.000043
Scan Speed
200.000000
Phase
10.546875
Y-Phase
0.122100
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SP Mirror 1 (left)
500.000000
SP Mirror 1 (right)
550.000000
SP Mirror 1 (stain) FITC FITC
SP Mirror 2 (left)
570.000000
SP Mirror 2 (right)
700.000000
SP Mirror 2 (stain) TRITC TRITC
SP Mirror 3 (left)
750.000000
SP Mirror 3 (right)
850.000000
SP Mirror 3 (stain) None None
Objective
HCX PL APO CS 40.0x1.25 OIL UV
40.0x1.25 OIL UV
Order number (Obj.)
506179
Numerical aperture (Obj.)
1.250000
SCANNER INFORMATION #1
RoiScan
0
IsSequential
0
ChaserUVShutter
0
ChaserVisibleShutter
0
MPShutter
0
UVShutter
0
VisibleShutter
1
ScanMode xyz
Active
Pinhole [m]
0.000081
Pinhole [airy]
0.998666
Size-Width [µm]
136.596680
Size-Height [µm]
136.596680
Size-Depth [µm]
0.325627
StepSize
[µm]
0.162813
Voxel-Width [µm]
0.266790
Voxel-Height [µm]
0.266790
Voxel-Depth [µm]
0.162813
Zoom
2.745308
Scan-Direction
1
Y-Scan-Direction
1
SequentialMode
0
Frame-Accumulation
1
Frame-Average
1
Line-Average
1
Resolution
8
Channels
2
Format-Width
512
Format-Height
512
Sections
84
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TIME INFORMATION #1
Stamped Dimension:
2
Stamp_0:
2007:06:19,15:45:23:593
Stamp_1:
2007:06:19,15:45:23:593
Stamp_2:
2007:06:19,15:45:26:843
Stamp_3:
2007:06:19,15:45:26:843
Stamp_4:
2007:06:19,15:45:30:93
Stamp_5:
2007:06:19,15:45:30:93
LUT DESCRIPTION #1
LUT_0
Name:
Green
Inverted (1=yes / 0=no): 0
LUT_1
Name:
Red
Inverted (1=yes / 0=no): 0
SEQUENTIAL INFORMATION #1
Sequence Count: 0
IMAGES INFORMATION #1
Number of Images: 6
Image Width:
512
Iamge Length:
512
Bits per Sample:
8
Samples per Pixel: 1
*************************************** NEXT IMAGE *********************************
DIMENSION DESCRIPTION #2
Pixel Size in Byte: 1
Resolution in Bit:
8
Max Value:
255.0000000000
Min Value:
0.000000e+000
Label:
I
Number of Dimensions:
4
Dimension_0:
120
Logical Size:
512
Physical Length:
1.372375e-004 m
Physical Origin:
0.000000e+000 m
Dimension_1:
121
Logical Size:
512
Physical Length:
1.372375e-004 m
Physical Origin:
0.000000e+000 m
Dimension_2:
6815843
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Logical Size:
Physical Length:
Physical Origin:
Dimension_3:
Logical Size:
Physical Length:
Physical Origin:
Series Name:
Description:

2
0.000000e+000
0.000000e+000
122
125
-2.018886e-005 m
-3.815939e-005 m
Series049

HARDWARE PARAMETER #2
AOTF (458)
49.328449
AOTF (476)
0.000000
AOTF (488)
50.671551
AOTF (514)
0.000000
AOTF (561)
50.012210
AOTF (633)
0.000000
AOTF (458)
0.000000
AOTF (476)
0.000000
AOTF (488)
0.000000
AOTF (514)
0.000000
AOTF (561)
0.000000
AOTF (633)
0.000000
PMT 1 Active Active
PMT 1 (Offs.)
-21.600000
PMT 1 (HV)
631.887456
PMT 2 Active Active
PMT 2 (Offs.)
-13.600000
PMT 2 (HV)
616.060961
PMT 3 Inactive
Inactive
PMT Trans Inactive
Inactive
Beam Expander
Beam Exp 6 Beam Exp 6
Excitation Beam Splitter FW
DD 488/568 DD 488/568
External Detection FW
Mirror Mirror
Hardware Type No.
2.000000
Scan Field Rotation
-0.038943
Rotation Direction
1
X Scan Actuator
Active Active
X Scan Actuator (Gain)
2.732488
X Scan Actuator (Offs.)
0.000000
Y Scan Actuator
Active Active
Y Scan Actuator (Gain)
2.732488
Y Scan Actuator (Offs.)
0.000000
Z Scan Actuator
Inactive
Inactive
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Z Scan Actuator (POS)
-0.000048
Scan Speed
200.000000
Phase
10.546875
Y-Phase
0.122100
SP Mirror 1 (left)
500.000000
SP Mirror 1 (right)
550.000000
SP Mirror 1 (stain) FITC FITC
SP Mirror 2 (left)
570.000000
SP Mirror 2 (right)
700.000000
SP Mirror 2 (stain) TRITC TRITC
SP Mirror 3 (left)
750.000000
SP Mirror 3 (right)
850.000000
SP Mirror 3 (stain) None None
Objective
HCX PL APO CS 40.0x1.25 OIL UV
40.0x1.25 OIL UV
Order number (Obj.)
506179
Numerical aperture (Obj.)
1.250000
SCANNER INFORMATION #2
RoiScan
0
IsSequential
0
ChaserUVShutter
0
ChaserVisibleShutter
0
MPShutter
0
UVShutter
0
VisibleShutter
1
ScanMode xyz
Active
Pinhole [m]
0.000081
Pinhole [airy]
0.998666
Size-Width [µm]
137.237549
Size-Height [µm]
137.237549
Size-Depth [µm]
-20.188864
StepSize
[µm]
0.162813
Voxel-Width [µm]
0.268042
Voxel-Height [µm]
0.268042
Voxel-Depth [µm]
0.162813
Zoom
2.732488
Scan-Direction
1
Y-Scan-Direction
1
SequentialMode
0
Frame-Accumulation
1
Frame-Average
1
Line-Average
1
Resolution
8
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Channels
Format-Width
Format-Height
Sections

2
512
512
125

TIME INFORMATION #2
Stamped Dimension:
2
Stamp_0:
2007:06:19,15:54:21:453
Stamp_1:
2007:06:19,15:54:21:453
Stamp_2:
2007:06:19,15:54:24:703
Stamp_3:
2007:06:19,15:54:24:703
Stamp_4:
2007:06:19,15:54:27:953
Stamp_5:
2007:06:19,15:54:27:953
Stamp_6:
2007:06:19,15:54:31:203
Stamp_7:
2007:06:19,15:54:31:203
Stamp_8:
2007:06:19,15:54:34:437
Stamp_9:
2007:06:19,15:54:34:437
Stamp_10: 2007:06:19,15:54:37:687
Stamp_11: 2007:06:19,15:54:37:687
Stamp_12: 2007:06:19,15:54:40:937
Stamp_13: 2007:06:19,15:54:40:937
Stamp_14: 2007:06:19,15:54:44:187
Stamp_15: 2007:06:19,15:54:44:187
Stamp_16: 2007:06:19,15:54:47:437
Stamp_17: 2007:06:19,15:54:47:437
Stamp_18: 2007:06:19,15:54:50:687
Stamp_19: 2007:06:19,15:54:50:687
Stamp_20: 2007:06:19,15:54:53:937
Stamp_21: 2007:06:19,15:54:53:937
Stamp_22: 2007:06:19,15:54:57:187
Stamp_23: 2007:06:19,15:54:57:187
Stamp_24: 2007:06:19,15:55:00:437
Stamp_25: 2007:06:19,15:55:00:437
Stamp_26: 2007:06:19,15:55:03:687
Stamp_27: 2007:06:19,15:55:03:687
Stamp_28: 2007:06:19,15:55:06:937
Stamp_29: 2007:06:19,15:55:06:937
Stamp_30: 2007:06:19,15:55:10:187
Stamp_31: 2007:06:19,15:55:10:187
Stamp_32: 2007:06:19,15:55:13:437
Stamp_33: 2007:06:19,15:55:13:437
Stamp_34: 2007:06:19,15:55:16:687
Stamp_35: 2007:06:19,15:55:16:687
Stamp_36: 2007:06:19,15:55:19:937
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Stamp_37:
Stamp_38:
Stamp_39:
Stamp_40:
Stamp_41:
Stamp_42:
Stamp_43:
Stamp_44:
Stamp_45:
Stamp_46:
Stamp_47:
Stamp_48:
Stamp_49:
Stamp_50:
Stamp_51:
Stamp_52:
Stamp_53:
Stamp_54:
Stamp_55:
Stamp_56:
Stamp_57:
Stamp_58:
Stamp_59:
Stamp_60:
Stamp_61:
Stamp_62:
Stamp_63:
Stamp_64:
Stamp_65:
Stamp_66:
Stamp_67:
Stamp_68:
Stamp_69:
Stamp_70:
Stamp_71:
Stamp_72:
Stamp_73:
Stamp_74:
Stamp_75:
Stamp_76:
Stamp_77:
Stamp_78:
Stamp_79:
Stamp_80:

2007:06:19,15:55:19:937
2007:06:19,15:55:23:187
2007:06:19,15:55:23:187
2007:06:19,15:55:26:437
2007:06:19,15:55:26:437
2007:06:19,15:55:29:687
2007:06:19,15:55:29:687
2007:06:19,15:55:32:937
2007:06:19,15:55:32:937
2007:06:19,15:55:36:187
2007:06:19,15:55:36:187
2007:06:19,15:55:39:437
2007:06:19,15:55:39:437
2007:06:19,15:55:42:687
2007:06:19,15:55:42:687
2007:06:19,15:55:45:937
2007:06:19,15:55:45:937
2007:06:19,15:55:49:187
2007:06:19,15:55:49:187
2007:06:19,15:55:52:437
2007:06:19,15:55:52:437
2007:06:19,15:55:55:687
2007:06:19,15:55:55:687
2007:06:19,15:55:58:937
2007:06:19,15:55:58:937
2007:06:19,15:56:02:187
2007:06:19,15:56:02:187
2007:06:19,15:56:05:437
2007:06:19,15:56:05:437
2007:06:19,15:56:08:687
2007:06:19,15:56:08:687
2007:06:19,15:56:11:937
2007:06:19,15:56:11:937
2007:06:19,15:56:15:187
2007:06:19,15:56:15:187
2007:06:19,15:56:18:437
2007:06:19,15:56:18:437
2007:06:19,15:56:21:687
2007:06:19,15:56:21:687
2007:06:19,15:56:24:937
2007:06:19,15:56:24:937
2007:06:19,15:56:28:187
2007:06:19,15:56:28:187
2007:06:19,15:56:31:437
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Stamp_81:
Stamp_82:
Stamp_83:
Stamp_84:
Stamp_85:
Stamp_86:
Stamp_87:
Stamp_88:
Stamp_89:
Stamp_90:
Stamp_91:
Stamp_92:
Stamp_93:
Stamp_94:
Stamp_95:
Stamp_96:
Stamp_97:
Stamp_98:
Stamp_99:
Stamp_100:
Stamp_101:
Stamp_102:
Stamp_103:
Stamp_104:
Stamp_105:
Stamp_106:
Stamp_107:
Stamp_108:
Stamp_109:
Stamp_110:
Stamp_111:
Stamp_112:
Stamp_113:
Stamp_114:
Stamp_115:
Stamp_116:
Stamp_117:
Stamp_118:
Stamp_119:
Stamp_120:
Stamp_121:
Stamp_122:
Stamp_123:
Stamp_124:

2007:06:19,15:56:31:437
2007:06:19,15:56:34:687
2007:06:19,15:56:34:687
2007:06:19,15:56:37:937
2007:06:19,15:56:37:937
2007:06:19,15:56:41:187
2007:06:19,15:56:41:187
2007:06:19,15:56:44:437
2007:06:19,15:56:44:437
2007:06:19,15:56:47:687
2007:06:19,15:56:47:687
2007:06:19,15:56:50:937
2007:06:19,15:56:50:937
2007:06:19,15:56:54:187
2007:06:19,15:56:54:187
2007:06:19,15:56:57:437
2007:06:19,15:56:57:437
2007:06:19,15:57:00:687
2007:06:19,15:57:00:687
2007:06:19,15:57:03:937
2007:06:19,15:57:03:937
2007:06:19,15:57:07:187
2007:06:19,15:57:07:187
2007:06:19,15:57:10:437
2007:06:19,15:57:10:437
2007:06:19,15:57:13:687
2007:06:19,15:57:13:687
2007:06:19,15:57:16:937
2007:06:19,15:57:16:937
2007:06:19,15:57:20:187
2007:06:19,15:57:20:187
2007:06:19,15:57:23:437
2007:06:19,15:57:23:437
2007:06:19,15:57:26:687
2007:06:19,15:57:26:687
2007:06:19,15:57:29:937
2007:06:19,15:57:29:937
2007:06:19,15:57:33:187
2007:06:19,15:57:33:187
2007:06:19,15:57:36:437
2007:06:19,15:57:36:437
2007:06:19,15:57:39:687
2007:06:19,15:57:39:687
2007:06:19,15:57:42:937
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Appendix E. (Continued)
Stamp_125:
Stamp_126:
Stamp_127:
Stamp_128:
Stamp_129:
Stamp_130:
Stamp_131:
Stamp_132:
Stamp_133:
Stamp_134:
Stamp_135:
Stamp_136:
Stamp_137:
Stamp_138:
Stamp_139:
Stamp_140:
Stamp_141:
Stamp_142:
Stamp_143:
Stamp_144:
Stamp_145:
Stamp_146:
Stamp_147:
Stamp_148:
Stamp_149:
Stamp_150:
Stamp_151:
Stamp_152:
Stamp_153:
Stamp_154:
Stamp_155:
Stamp_156:
Stamp_157:
Stamp_158:
Stamp_159:
Stamp_160:
Stamp_161:
Stamp_162:
Stamp_163:
Stamp_164:
Stamp_165:
Stamp_166:
Stamp_167:
Stamp_168:

2007:06:19,15:57:42:937
2007:06:19,15:57:46:187
2007:06:19,15:57:46:187
2007:06:19,15:57:49:437
2007:06:19,15:57:49:437
2007:06:19,15:57:52:687
2007:06:19,15:57:52:687
2007:06:19,15:57:55:921
2007:06:19,15:57:55:921
2007:06:19,15:57:59:171
2007:06:19,15:57:59:171
2007:06:19,15:58:02:421
2007:06:19,15:58:02:421
2007:06:19,15:58:05:671
2007:06:19,15:58:05:671
2007:06:19,15:58:08:921
2007:06:19,15:58:08:921
2007:06:19,15:58:12:171
2007:06:19,15:58:12:171
2007:06:19,15:58:15:421
2007:06:19,15:58:15:421
2007:06:19,15:58:18:671
2007:06:19,15:58:18:671
2007:06:19,15:58:21:921
2007:06:19,15:58:21:921
2007:06:19,15:58:25:171
2007:06:19,15:58:25:171
2007:06:19,15:58:28:421
2007:06:19,15:58:28:421
2007:06:19,15:58:31:671
2007:06:19,15:58:31:671
2007:06:19,15:58:34:921
2007:06:19,15:58:34:921
2007:06:19,15:58:38:171
2007:06:19,15:58:38:171
2007:06:19,15:58:41:421
2007:06:19,15:58:41:421
2007:06:19,15:58:44:671
2007:06:19,15:58:44:671
2007:06:19,15:58:47:921
2007:06:19,15:58:47:921
2007:06:19,15:58:51:171
2007:06:19,15:58:51:171
2007:06:19,15:58:54:421
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Appendix E. (Continued)
Stamp_169:
Stamp_170:
Stamp_171:
Stamp_172:
Stamp_173:
Stamp_174:
Stamp_175:
Stamp_176:
Stamp_177:
Stamp_178:
Stamp_179:
Stamp_180:
Stamp_181:
Stamp_182:
Stamp_183:
Stamp_184:
Stamp_185:
Stamp_186:
Stamp_187:
Stamp_188:
Stamp_189:
Stamp_190:
Stamp_191:
Stamp_192:
Stamp_193:
Stamp_194:
Stamp_195:
Stamp_196:
Stamp_197:
Stamp_198:
Stamp_199:
Stamp_200:
Stamp_201:
Stamp_202:
Stamp_203:
Stamp_204:
Stamp_205:
Stamp_206:
Stamp_207:
Stamp_208:
Stamp_209:
Stamp_210:
Stamp_211:
Stamp_212:

2007:06:19,15:58:54:421
2007:06:19,15:58:57:671
2007:06:19,15:58:57:671
2007:06:19,15:59:00:921
2007:06:19,15:59:00:921
2007:06:19,15:59:04:171
2007:06:19,15:59:04:171
2007:06:19,15:59:07:421
2007:06:19,15:59:07:421
2007:06:19,15:59:10:671
2007:06:19,15:59:10:671
2007:06:19,15:59:13:921
2007:06:19,15:59:13:921
2007:06:19,15:59:17:171
2007:06:19,15:59:17:171
2007:06:19,15:59:20:421
2007:06:19,15:59:20:421
2007:06:19,15:59:23:671
2007:06:19,15:59:23:671
2007:06:19,15:59:26:921
2007:06:19,15:59:26:921
2007:06:19,15:59:30:171
2007:06:19,15:59:30:171
2007:06:19,15:59:33:421
2007:06:19,15:59:33:421
2007:06:19,15:59:36:671
2007:06:19,15:59:36:671
2007:06:19,15:59:39:921
2007:06:19,15:59:39:921
2007:06:19,15:59:43:171
2007:06:19,15:59:43:171
2007:06:19,15:59:46:421
2007:06:19,15:59:46:421
2007:06:19,15:59:49:671
2007:06:19,15:59:49:671
2007:06:19,15:59:52:921
2007:06:19,15:59:52:921
2007:06:19,15:59:56:171
2007:06:19,15:59:56:171
2007:06:19,15:59:59:421
2007:06:19,15:59:59:421
2007:06:19,16:00:02:671
2007:06:19,16:00:02:671
2007:06:19,16:00:05:921
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Appendix E. (Continued)
Stamp_213:
Stamp_214:
Stamp_215:
Stamp_216:
Stamp_217:
Stamp_218:
Stamp_219:
Stamp_220:
Stamp_221:
Stamp_222:
Stamp_223:
Stamp_224:
Stamp_225:
Stamp_226:
Stamp_227:
Stamp_228:
Stamp_229:
Stamp_230:
Stamp_231:
Stamp_232:
Stamp_233:
Stamp_234:
Stamp_235:
Stamp_236:
Stamp_237:
Stamp_238:
Stamp_239:
Stamp_240:
Stamp_241:
Stamp_242:
Stamp_243:
Stamp_244:
Stamp_245:
Stamp_246:
Stamp_247:
Stamp_248:
Stamp_249:

2007:06:19,16:00:05:921
2007:06:19,16:00:09:171
2007:06:19,16:00:09:171
2007:06:19,16:00:12:421
2007:06:19,16:00:12:421
2007:06:19,16:00:15:671
2007:06:19,16:00:15:671
2007:06:19,16:00:18:921
2007:06:19,16:00:18:921
2007:06:19,16:00:22:171
2007:06:19,16:00:22:171
2007:06:19,16:00:25:421
2007:06:19,16:00:25:421
2007:06:19,16:00:28:671
2007:06:19,16:00:28:671
2007:06:19,16:00:31:921
2007:06:19,16:00:31:921
2007:06:19,16:00:35:171
2007:06:19,16:00:35:171
2007:06:19,16:00:38:421
2007:06:19,16:00:38:421
2007:06:19,16:00:41:671
2007:06:19,16:00:41:671
2007:06:19,16:00:44:921
2007:06:19,16:00:44:921
2007:06:19,16:00:48:171
2007:06:19,16:00:48:171
2007:06:19,16:00:51:421
2007:06:19,16:00:51:421
2007:06:19,16:00:54:671
2007:06:19,16:00:54:671
2007:06:19,16:00:57:921
2007:06:19,16:00:57:921
2007:06:19,16:01:01:171
2007:06:19,16:01:01:171
2007:06:19,16:01:04:421
2007:06:19,16:01:04:421

LUT DESCRIPTION #2
LUT_0
Name:
Green
Inverted (1=yes / 0=no): 0
LUT_1
Name:
Red
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Appendix E. (Continued)
Inverted (1=yes / 0=no):

0

SEQUENTIAL INFORMATION #2
Sequence Count: 0
IMAGES INFORMATION #2
Number of Images: 250
Image Width:
512
Iamge Length:
512
Bits per Sample:
8
Samples per Pixel: 1
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